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ABSTRACT OF THE DISSERTATION 
 
A SPARSE ORTHOGONAL COLLIMATOR FOR SMALL ANIMAL INTENSITY MODULATED 
RADIATION THERAPY USING RECTANGULAR APERTURE OPTIMIZATION 
 
by 
 
Kaley Elizabeth Woods 
Doctor of Philosophy in Biomedical Physics 
University of California, Los Angeles, 2019 
Professor Ke Sheng, Chair 
 
 
 To achieve more translatable preclinical research results, small animal irradiation 
needs to more closely simulate human radiation therapy. Although the clinical gold standard 
is intensity modulated radiation therapy (IMRT), the direct translation of this method for 
small animals is impractical. To address this challenge, the Sparse Orthogonal Collimator 
(SOC), a dose-modulating device based on the novel Rectangular Aperture Optimization 
(RAO) approach, was developed to deliver IMRT on the small animal scale using an image-
guided small animal irradiator. 
 iii 
 A treatment planning system was developed based on RAO, and several planning 
experiments were performed for evaluation. RAO achieved highly conformal doses to 
concave and complex targets, with SOC-based plans achieving superior dosimetry to those 
optimized for a hypothetical miniature multileaf collimator. Beam commissioning data, 
including output factors, off-axis factors, and percent depth dose curves, were acquired for 
our small animal irradiator and incorporated into the treatment planning system. A plan 
post-processing step was implemented for aperture-size-specific dose recalculation and 
aperture weighting reoptimization. 
 The SOC system, with four orthogonal, double-focused tungsten leaf pairs, was 
designed and fabricated, and control software was developed. The SOC was installed on the 
small animal irradiator and the alignment was evaluated, with submillimeter shifts 
measured between the SOC and primary collimator axes over the full gantry rotation. 
Abutting field and grid dose patterns were created to analyze leaf positioning error, with 
measured deviations within recommended guidelines. Extremely low leaf transmission was 
measured, and penumbra was independent of leaf position. Three RAO IMRT plans were 
delivered and analyzed, with good agreement between the intended and measured dose 
distributions. 
 By using advanced optimization techniques, complex IMRT plans were achieved 
using a simple dose modulation device. The sparse orthogonal collimator was developed and 
commissioned, with promising preliminary dosimetry results. This platform considerably 
reduces the gap in treatment plan quality between clinical and preclinical radiotherapy, 
potentially improving the translation of small animal research results. 
 iv 
The dissertation of Kaley Elizabeth Woods is approved. 
Keisuke Steven Iwamoto 
Dan Ruan 
Erik Tryggestad 
Ke Sheng, Committee Chair 
 
 
 
University of California, Los Angeles 
2019 
 
 
 
 
 
 
 
 
 
 v 
 
 
 
To Mom, Dad, and Kris 
 
 
  
 vi 
TABLE OF CONTENTS 
LIST OF TABLES..................................................................................................................................................... IX 
LIST OF FIGURES ..................................................................................................................................................... X 
LIST OF EQUATIONS......................................................................................................................................... XV 
ACKNOWLEDGEMENTS ....................................................................................................................................... XVI 
VITA .................................................................................................................................................................... XVII 
1 INTRODUCTION ................................................................................................................................... 1 
1.1 4Π RADIOTHERAPY......................................................................................................................................... 2 
1.2 PRECLINICAL RADIOTHERAPY ....................................................................................................................... 3 
1.3 OVERVIEW ....................................................................................................................................................... 4 
2 4Π RADIOTHERAPY ............................................................................................................................ 7 
2.1 VIABILITY OF NONCOPLANAR VMAT FOR LIVER SBRT COMPARED WITH COPLANAR VMAT AND 
BEAM ORIENTATION OPTIMIZED 4Π IMRT26 ................................................................................................... 7 
2.1.1 Introduction ................................................................................................................................................ 7 
2.1.2 Methods ......................................................................................................................................................... 8 
2.1.3 Results ......................................................................................................................................................... 15 
2.1.4 Discussion .................................................................................................................................................. 21 
2.1.5 Conclusions ............................................................................................................................................... 24 
2.2 COCHLEA-SPARING ACOUSTIC NEUROMA TREATMENT WITH 4Π RADIATION THERAPY27 .................25 
2.2.1 Introduction ............................................................................................................................................. 25 
2.2.2 Methods ...................................................................................................................................................... 27 
2.2.3 Results ......................................................................................................................................................... 33 
2.2.4 Discussion .................................................................................................................................................. 37 
2.2.5 Conclusions ............................................................................................................................................... 40 
2.3 4Π PLAN OPTIMIZATION FOR CORTICAL-SPARING BRAIN RADIOTHERAPY28 .......................................41 
2.3.1 Introduction ............................................................................................................................................. 41 
2.3.2 Methods ...................................................................................................................................................... 42 
2.3.3 Results ......................................................................................................................................................... 44 
2.3.4 Discussion .................................................................................................................................................. 47 
2.3.5 Conclusions ............................................................................................................................................... 48 
 vii 
3 DOSIMETRIC EVALUATION TOOLS FOR PRECLINICAL RADIOTHERAPY ...................... 49 
3.1 SMALL ANIMAL IRRADIATION STANDARDIZATION PROJECT ...................................................................49 
3.1.1 Introduction ............................................................................................................................................. 49 
3.1.2 Methods ...................................................................................................................................................... 50 
3.1.3 Results and Discussion ......................................................................................................................... 56 
3.1.4 Conclusions ............................................................................................................................................... 59 
3.2 A 3D PRINTED, CT-GENERATED MONKEY PHANTOM WITH TISSUE AND BONE EQUIVALENT 
MATERIALS ...........................................................................................................................................................60 
3.2.1 Introduction ............................................................................................................................................. 60 
3.2.2 Methods ...................................................................................................................................................... 60 
3.2.3 Results ......................................................................................................................................................... 62 
3.2.4 Discussion .................................................................................................................................................. 64 
3.2.5 Conclusions ............................................................................................................................................... 64 
4 SOC PLANNING SYSTEM DEVELOPMENT AND COMMISSIONING ..................................... 66 
4.1 INTRODUCTION .............................................................................................................................................66 
4.2 METHODS ......................................................................................................................................................69 
4.2.1 Rectangular Aperture Optimization .............................................................................................. 69 
4.2.2 RAO Evaluation ....................................................................................................................................... 71 
4.2.3 Beam Commissioning Measurements............................................................................................ 73 
4.2.4 Plan Post-Processing ............................................................................................................................ 76 
4.3 RESULTS ........................................................................................................................................................78 
4.3.1 RAO Plan Analysis .................................................................................................................................. 78 
4.3.2 Beam Commissioning ........................................................................................................................... 81 
4.3.3 Dose Recalculation ................................................................................................................................ 85 
4.4 DISCUSSION ...................................................................................................................................................87 
4.5 CONCLUSIONS ................................................................................................................................................90 
5 SOC HARDWARE DEVELOPMENT AND COMMISSIONING ................................................... 91 
5.1 INTRODUCTION .............................................................................................................................................91 
5.2 METHODS ......................................................................................................................................................93 
5.2.1 SOC Design ................................................................................................................................................ 93 
 viii 
5.2.2 SOC Fabrication ...................................................................................................................................... 97 
5.2.3 SOC Control Software ........................................................................................................................... 99 
5.2.4 SOC Installation .................................................................................................................................... 100 
5.2.5 SOC Commissioning Measurements ............................................................................................. 103 
5.2.6 Dosimetric Testing .............................................................................................................................. 105 
5.3 RESULTS ..................................................................................................................................................... 107 
5.3.1 SOC Commissioning ............................................................................................................................. 107 
5.3.2 Dosimetric Testing .............................................................................................................................. 112 
5.4 DISCUSSION ................................................................................................................................................ 115 
5.5 CONCLUSIONS ............................................................................................................................................. 120 
6 REFERENCES ................................................................................................................................... 121 
  
 ix 
LIST OF TABLES 
Table 2-1 Patient Data ......................................................................................................................................... 9 
Table 2-2 Average dose statistics for coplanar VMAT, noncoplanar VMAT, and 4π plans for 
all 20 patients (HI: homogeneity index, CN: conformation number) ................................... 16 
Table 2-3 Biological modeling parameter results for cVMAT, nVMAT, and 4π plans for all 20 
patients (standard deviation in parentheses) ............................................................................... 19 
Table 2-4 Dose escalation based on the normal liver effective volume and desired normal 
liver LKB NTCP for all 20 patients (standard deviation in parentheses) ........................... 20 
Table 2-5 Patient data ...................................................................................................................................... 28 
Table 2-6 TCP and NTCP model parameters ........................................................................................... 32 
Table 2-7 OAR doses and conformity measures for both plan types............................................. 34 
Table 2-8 Results of the radiobiological modeling and dose escalation study .......................... 36 
Table 2-9 Dose statistics for clinical and 4π plans for the 15 high-grade glioma patients in 
this study...................................................................................................................................................... 45 
Table 3-1 Energy correction factors for TLD, OSLD, and EBT3 film measurements ............... 55 
Table 4-1 SmART system beam commissioning measurement parameters .............................. 75 
Table 4-2 Dose evaluation metrics for the mouse test cases (R50: 50% dose spillage; CN: 
Conformation Number) .......................................................................................................................... 79 
Table 4-3 Simplified off-axis factor measurements for 1, 2.5, and 5 mm square SOC fields on 
the SmART system, averaged over nine equal regions for comparison .............................. 83 
Table 4-4 Field flatness for a 40 mm square field on the SmART system .................................... 85 
Table 4-5 Error comparison for plans optimized with different dose calculation spectra ... 86 
Table 5-1 SOC test plan parameters ......................................................................................................... 106 
Table 5-2 Leaf positioning accuracy and repeatability measurements ...................................... 109 
Table 5-3 SOC leaf transmission and penumbra measurements .................................................. 111 
Table 5-4 Comparisons between the measured and intended dose distributions for the C-
shaped target plan and the mouse phantom whole liver plana ............................................ 114 
 x 
LIST OF FIGURES 
Figure 2-1 Beam geometry comparison for a typical liver SBRT case. Beam orientation is shown 
for the coplanar VMAT plan (left), 3 to 4 noncoplanar partial arcs (center) and 20 
noncoplanar, optimized beams (right). ................................................................................................. 12 
Figure 2-2 Individual patient dosimetric results comparison between cVMAT, nVMAT, and 
4π static. ....................................................................................................................................................... 17 
Figure 2-3 (Top) Dose-volume histograms for a typical liver SBRT case. (Bottom) Dose color 
washes for each plan type. The orange contours represent the PTV volume and the blue 
represent the 50% isodose lines. ....................................................................................................... 18 
Figure 2-4 Average survival predicted with the model from Tai et al49 for the maximum 
tolerable doses yielding 1%, 5%, and 10% normal liver NTCPs. All fractions for nVMAT 
and cVMAT were significantly different than 4π static at the 5% significance level 
(paired, 2-tailed t-test). .......................................................................................................................... 21 
Figure 2-5 Examples of typical beam orientations for the clinical plans with 7 to 11 static 
beams (left), clinical plans with 2 to 5 arcs (middle), and 4π plans with 20 static beams 
(right). From Table 2-5, these are patients 16, 4, and 1, respectively. ................................ 30 
Figure 2-6 Mean (top) and maximum (bottom) doses to the cochlea (SRS, SRT, and IMRT 
groups), brainstem, and chiasm with the 4π plans (red) and clinical plans (blue). All 
differences between the 4π and clinical plans were statistically significant (2-tailed t-
test, 5% significance level), except the maximum dose to the chiasm. ............................... 34 
Figure 2-7 Dose color wash for a patient (patient 3 in Table 2-5) who was treated to a 
prescription dose of 12 Gy in a single fraction. Structures: PTV (blue), brainstem (green), 
and cochlea (red). ..................................................................................................................................... 35 
Figure 2-8 Dose volume histograms (solid line: clinical plan; dashed line: 4π plan) for one of 
the patients who received SRS in this study (patient 2 in Table 2-5) with a prescription 
dose of 12 Gy. ............................................................................................................................................. 37 
Figure 2-9 A representation of the cortical surface from Karunamuni et al90 showing the dose 
delivered (A) and the extent of cortical thinning one year post-irradiation (B) for an 
example patient. ........................................................................................................................................ 41 
Figure 2-10 Orientation of the beams used in the clinical IMRT plan (left) and the 20 optimal 
beams selected by the 4π algorithm (right) for one patient in the study. .......................... 44 
Figure 2-11 Dose volume histograms of the 4π (dashed) and clinical (solid) plans for the 
patient in Figure 2-10. ............................................................................................................................ 46 
 xi 
Figure 2-12 Dose washes of the 4π and clinical plans for the patient in Figure 2-10. 
Structures: 54 Gy PTV (green), 60 Gy PTV (blue), and cerebral cortex (gray). ................ 46 
Figure 2-13 Dose volume histograms of the cortex and PTV (60 Gy prescription level) for the 
4π (dashed) and clinical (solid) plans averaged over all 15 patients. ................................. 47 
Figure 3-1 Photograph (left) and CT scan (right: coronal view of the lower (A) and upper (B) 
phantom halves; axial view through the lungs (C)) of the cylindrical polystyrene mouse 
phantoms, with higher density inserts in the spine and legs and lower density foam 
inserts in the lungs. It has groups of three TLD slots in the head, spine, left and right 
abdomen, and pelvis. Custom die-cut film is inserted between the two halves. ............. 50 
Figure 3-2  CAD models of the full mousemorphic phantom with dimensions (upper left) and 
the design variations for TLD, OSLD, and Alanine dosimetry. ................................................ 52 
Figure 3-3 Phantoms 3D printed out of ABS from the CAD model shown in Figure 3-2. The 
weight of the phantom is 24.5 ± 0.1 g. .............................................................................................. 52 
Figure 3-4 Monte Carlo dose calculation in the SmART-ATP system assuming tissue 
equivalence (left) and measured phantom film dose (right). ................................................. 53 
Figure 3-5 Film measurement from one of the cylindrical mouse phantoms. Average dose 
was measured within the four regions indicated by red squares. ........................................ 56 
Figure 3-6 Dosimetric harmonization test results. Measured dose is given as the average dose 
from the four regions-of-interest of the cylindrical phantom film (as shown in Figure 
3-5) with error bars indicating the standard deviation. Irradiators #6 and #8 did not 
participate in the first survey, and the harmonization result of #3 was not valid. The 
exposure parameter for #5 was not adjusted. .............................................................................. 57 
Figure 3-7 CAD model of the portable phantom developed for beam energy spectrum 
characterization. Each region of the phantom has the same thickness of plastic (left), 
above four different thickness of copper (center). Below the copper there are inserts for 
three TLDs in each region, including the 0 mm region (right). Film is inserted above the 
TLDs, with a shim in between to prevent scatter. ....................................................................... 58 
Figure 3-8 (Left) The measured film distribution for one of the half-value layer (HVL) 
experiments, with labels for the copper thickness above each region. (Right) Measured 
film doses (normalized to 1) and best-fit exponential curves for the HVL phantom 
irradiated with 300 kV x-rays, 225 kV x-rays with an aluminum filter, and 225 kV x-rays 
with a copper filter. A simple exponential relationship cannot accurately model the 
attenuation of polyenergetic beams, which is most evident for the 225 kV beam with 
aluminum filtration. ................................................................................................................................. 59 
 xii 
Figure 3-9 3D printed monkey phantom parts. The bone segments were printed out of 
Ceramic Resin (left) and soft tissue out of Flexible Resin (center). Inserts in the phantom 
abdomen and chest were designed for TLD dosimetry (right). ............................................. 62 
Figure 3-10 CT images for the real monkey (left) and phantom (right) in the pelvis (upper) 
and spine (lower). The center slit in the phantom pelvis was designed for film insertion. 
Measured HU values for ROIs in the soft tissue and bone (shown in green) are given on 
the right. (HU: Hounsfield Units) ........................................................................................................ 63 
Figure 3-11 (Left) Calculated dose for the phantom test plan, with a prescription dose of 8 
Gy to a 10 mm target in the phantom chest delivered in one full arc. Real tissue, lung, 
and bone material properties were used for dose calculation. (Right) Measured dose 
from film inserted into the midsagittal slit in the phantom chest, at the same plane as 
the calculated dose shown in the center. ........................................................................................ 63 
Figure 4-1 (Upper) Calculated concave dose distribution (with colorbar units in Gy) in the 
mouse brain delivered with a hypothetical MLC (A) and the SOC (B). Simultaneous 
integrated boost SOC plan (C) with a 125% dose boost to the overlapping target region. 
(Lower) Dose volume histogram comparisons for plans in (A-C). The SOC plans show a 
more homogeneous dose with less high dose spillage using the same number of 
segments. ..................................................................................................................................................... 79 
Figure 4-2 Dose volume histograms (left) and dose wash (right) for the mouse phantom 
whole liver irradiation plan, optimized with RAO. In both images, the liver (target) is 
shown in teal, body in yellow, and kidneys in red. ...................................................................... 80 
Figure 4-3 (Left) Target image for the Audrey Hepburn plan, with 4 dose levels of 0, 2, 4, and 
6 Gy. (Right) Optimized dose distribution from RAO with 1 mm beamlet and minimum 
aperture size. The optimized plan used 551 apertures with an average size of 2.4 mm.
.......................................................................................................................................................................... 81 
Figure 4-4 Measured output factors (average and standard deviation shown for 4 
measurements) for the SmART system, calculated as a fraction of the full 26 mm SOC 
field................................................................................................................................................................. 82 
Figure 4-5 The 2.5 mm field off-axis dose film map (left), mean dose measurement map 
(center), and final interpolated off-axis factor map (right). .................................................... 83 
Figure 4-6 Measured percent depth dose curves for different field sizes on the SmART (solid 
lines) and for the energy spectra optimized to match each measured curve (dashed 
lines). ............................................................................................................................................................. 84 
Figure 4-7 (Upper) Difference from the recalculated (field size-specific) dose for each 
optimization spectrum. (Lower) Dose optimized with the 1 mm field calculation 
spectrum (left), difference between the optimized dose and the recalculated dose, with 
 xiii 
a mean of 1.2% and maximum of 11.0% of the maximum plan dose (middle), difference 
between the optimized dose and the dose after reoptimization of the aperture 
weightings, with a mean of 1.2% and a maximum of 7.3% of the maximum plan dose 
(right). All dose distributions are shown at the target depth of 2 mm. (Dopt: original 
optimized dose; Drecalc: optimized dose recalculated based on aperture size; Dreopt: dose 
after reoptimization of aperture weightings) ............................................................................... 87 
Figure 5-1 Leaf designs for the SOC, with dimensions shown in millimeters. Upper and lower 
leaf sets feature different radii of curvature and different geometry for the outer 
stabilizing tongues (along the top/bottom for upper/lower leaves, respectively). Each 
tongue and groove pair also has a mirroring pair with the tab on the opposite end..... 95 
Figure 5-2 CAD model of the SOC. (A) Leaves connected to motor shafts with 3D printed rods 
and pins. (B) Stepper motor pair screwed into housing. (C) Outer leaf tongues slide along 
rails in housing. Shown in each corner of the SOC field are tungsten inserts for shielding 
the corners of the larger 4 x 4 cm primary collimator field. (D) All four orthogonal leaf 
banks. (E) Covers slide into the housing over each motor bank. (F) Main housing top 
attached, with mount for square primary collimator. (G) Complete SOC system with 
adapter to the primary 4x4 cm square SmART collimator. The collimator slides tightly 
into the adapter with a screw clamp for added support. The C-shaped attachment 
around the adapter guides the motor cables to the main socket on the back of the SOC.
.......................................................................................................................................................................... 96 
Figure 5-3 The SOC mounted onto the gantry of the SmART system via the primary 4 cm fixed 
collimator. .................................................................................................................................................... 97 
Figure 5-4 Machining of the prototype tungsten alloy leaves for the SOC. ................................. 97 
Figure 5-5 3D printed SOC housing: main SOC leaf housing (upper left); outer leaf tongues 
slide along housing rails (upper middle); leaves attached to motors with 3D printed rods 
and pins (upper right); housing with all 8 SOC leaves (lower left); housing top with 
opening for 4 x 4 cm primary collimator and cable guide attachment (lower middle); 
housing for Arduino board and motor driver boards (lower right). .................................... 98 
Figure 5-6 Graphic user interface for SOC control, with an aperture sequence loaded from a 
JavaScript Object Notation (JSON) file. Apertures can be edited and saved using the 
Sequence Item Editor shown. Leaves can also be controlled by dragging the gray 
“leaves” on the left. The “Calibrate Leaflet Positions” feature can also be used to set a 
new leaf “zero” position. ...................................................................................................................... 100 
Figure 5-7. SOC installed on SmART system, attached to the 4 x 4 square primary collimator.
........................................................................................................................................................................ 101 
Figure 5-8 SOC leaf position calibration procedure using the fluoroscopy mode of the SmART 
system calibration software. (Upper) SOC axes are determined from the inner leaf edges. 
 xiv 
(Lower) open leaf positions are set to the desired distance from each axis and the new 
calibration is saved with the SOC GUI. ............................................................................................ 102 
Figure 5-9 (Left) Mouse phantom modeled from mouse CT data and 3D printed with a 
flexible, tissue-equivalent material and a mid-coronal split for film measurement. 
Phantom is shown on the previously mentioned rotating couch mount. (Right) 3D 
printed block phantom for axial dose measurements. ............................................................ 105 
Figure 5-10 (Left) The measured offsets between the SOC field center and treatment 
isocenter at each projection angle in the x (blue) and y (red) directions are shown with 
solid lines. The difference between the offsets with the SOC (mounted on the primary 
collimator) and the primary collimator alone (S40) are shown with dotted lines. (Right) 
Spoke shot pattern from 1 mm slit SOC fields delivered at 8 equally spaced angles, 
measured perpendicular to the rotational axis and shown with a 2 Gy minimum dose 
cutoff. ........................................................................................................................................................... 108 
Figure 5-11 Abutting field film patterns for the upper (left) and lower (center) leaves, 
normalized to the average field dose. (Right) One of the alignment verification grid 
patterns delivered with the SOC, normalized to the maximum dose. ................................ 109 
Figure 5-12 (Left) Calculated dose distribution of the C-shaped target plan perpendicular to 
the gantry rotation axis. (Center) Measured film dose distribution from the center of the 
solid water phantom for the C target plan delivered with the SOC. Both plans are shown 
with the same color scale, in units of Gy. (Right) A comparison of the calculated (yellow) 
and measured (blue) 50% isodose lines, with overlapping regions shown in red. ...... 113 
Figure 5-13 (A) Mid-coronal view of the calculated dose for the mouse phantom whole liver 
plan (units of Gy). (B) The 5 optimal coplanar beam angles selected with the 4π 
algorithm. (C) Measured film dose from the mouse phantom, treated with the whole 
liver plan, at the plane shown in (A) (units of Gy). (D) A comparison of the calculated 
(yellow) and measured (blue) 60% isodose lines, with overlapping regions shown in 
red. Target structure was rotated to account for slight phantom misalignment, which 
also resulted in the truncated lower left portion of the target. ............................................ 114 
Figure 5-14 (Left) Calculated Audrey test plan with 4 dose levels and an average aperture 
size of 2.35 mm. (Right) Measured dose distribution of the Audrey plan delivered with 
the SOC. Both plans are shown with the same color scale, in units of Gy. ........................ 115 
 xv 
LIST OF EQUATIONS 
Equation 2-1 13 
Equation 2-2 14 
Equation 2-3 15 
Equation 2-4 30 
Equation 2-5 31 
Equation 4-1 70 
 
  
 xvi 
ACKNOWLEDGEMENTS 
 I would first like to express my deepest thanks to my advisor, Dr. Ke Sheng, for all 
his guidance over the last five years. I am so grateful to have had such a supportive and 
understanding mentor. His knowledge, curiosity, and passion for medical physics has 
inspired and motivated me throughout my graduate career. 
 I am also sincerely grateful to the rest of my dissertation committee, Dr. Dan Ruan, 
Dr. Kei Iwamoto, and Dr. Erik Tryggestad. Their fresh perspectives and insightful feedback 
have been extremely valuable to this work. 
 I would also like to thank Dr. Michael McNitt-Gray and Reth Im for everything they 
do for the Physics and Biology in Medicine program. I cannot imagine a graduate program 
that cares more about the success and overall well-being of its students. 
 I could not have done this without the help and friendship of my labmates, Victoria, 
Dan, Angelia, Daniel, Ryan, Wenbo, Elizabeth, Qihui, and Daili. I cannot wait to see the great 
things that they all will accomplish. I was lucky to be part of a lab with so much opportunity 
for collaboration and growth.  
 I am eternally grateful to my parents for their constant support in everything I do. 
All of my accomplishments have been possible because of them and the opportunities they 
have provided for me. A big thanks to my brothers as well for cheering me on but always 
keeping me humble. Finally, I want to thank Kris for believing in me far more than I believe 
in myself. His love and encouragement got me through the final stretch. 
 
 xvii 
VITA 
EDUCATION 
M.S.   University of California, Los Angeles, Biomedical Physics                     2017 
B.S.   University of California, Los Angeles, Bioengineering       2012 
 
AWARDS 
Moses A. Greenfield Award            2018 
Norm Baily Award (AAPM Southern California Chapter)        2018 
 
PEER-REVIEWED PUBLICATIONS 
1. K. Woods, D. Nguyen, R. Neph, D. Ruan, D. O’Connor, K. Sheng. “A Sparse Orthogonal 
Collimator for Small Animal Intensity Modulated Radiation Therapy, Part I: Planning 
System Development and Commissioning,” In submission. 
2. K. Woods, R. Neph, D. Nguyen, K. Sheng. “A Sparse Orthogonal Collimator for Small 
Animal Intensity Modulated Radiation Therapy, Part II: Hardware Development and 
Commissioning,” In submission. 
3. V.L. Murzin, K. Woods, V. Moiseenko, R. Karunamuni, K. Tringale, T. Seibert, M. 
Connor, D. Simpson, K. Sheng, J. Hattangadi-Gluth, “4π plan optimization for cortical-
sparing brain radiotherapy,” Radiotherapy and Oncology, 127(1): 128-135 (2018). 
4. K. Woods, P. Lee, T. Kaprealian, I. Yang, K. Sheng, “Cochlea-sparing acoustic neuroma 
treatment with 4π radiation therapy,” Advances in Radiation Oncology, 3(2): 100-107 
(2018). 
5. V. Yu, A. Landers, K. Woods, D. Nguyen, M. Cao, R.K. Chin, D. Du, K. Sheng, T.B. 
Kaprealian, “A prospective 4π radiotherapy clinical study in recurrent high grade 
glioma patients,” Int J Radiat Oncol Biol Phys, 101: 144-151 (2018). 
6. A. Tran, K. Woods, D. Nguyen, V. Yu, T. Niu, M. Cao, P. Lee, K. Sheng, “Predicting liver 
SBRT eligibility and plan quality for VMAT and 4π plans,” Radiation Oncology, 12(1): 
70 (2017). 
7. A. Tran, J. Zhang, K. Woods, V. Yu, D. Nguyen, G. Gustafson, L. Rosen, K. Sheng, 
“Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate 
cases,” Radiation Oncology, 12(1): 10 (2017).  
8. D. Nguyen, D. Ruan, D. O’Connor, K. Woods, D. Low, S. Boucher, K. Sheng, “A novel 
software and conceptual design of the hardware platform for intensity modulated 
radiation therapy,” Medical Physics, 43(2): 917-929 (2016). 
 xviii 
9. K. Woods, D. Nguyen, A. Tran, V. Yu, M. Cao, T. Niu, P. Lee, K. Sheng, “Viability of 
noncoplanar VMAT for liver SBRT compared with coplanar VMAT and beam 
orientation optimized 4π IMRT,” Advances in Radiation Oncology, 1(1): 67-75 (2016). 
10. P. Dong, V. Yu, D. Nguyen, J. Demarco, K. Woods, S. Boucher, D. Low, K. Sheng, 
“Feasibility of using intermediate x-ray energies for highly conformal extracranial 
radiotherapy,” Medical Physics, 41(4): 041709 (2014).  
 
SELECTED CONFERENCE PRESENTATIONS 
1. K. Woods, D. Nguyen, R. Neph, D. O’Connor, S. Boucher, K. Sheng (2018, 
July/October). “Sparse Orthogonal Collimator with Rectangular Aperture 
Optimization for Small Animal IMRT,” AAPM Annual Meeting, Nashville, TN, and 
ASTRO Annual Meeting, San Antonio, TX. 
2. K. Woods (2018, July). “Shaping Pre-Clinical Radiotherapy Research,” MedPhys Slam 
National Competition – AAPM Annual Meeting, Nashville, TN. 
3. K. Woods, D. Nguyen, D. Ruan, D. O’Connor, K. Sheng (2017, July). “Double-Focused 
Sparse Orthogonal Collimator Design for Small Animal X-Ray Irradiators,” AAPM 
Annual Meeting, Denver, CO. 
4. K. Woods, M. Harrison, S. Boucher, J. McNevin, S. Kutsaev, L. Faillace, K. Sheng (2016, 
August). “Novel Hardware and Software Platform for Intermediate Energy 4π 
Radiotherapy,” AAPM Annual Meeting, Washington, D.C.  
5. K. Woods, R. Karunamuni, A. Tran, V. Yu, D. Nguyen, J. Hattangadi-Gluth, K. Sheng 
(2016, August). “Dosimetric Comparison of 4π and Clinical IMRT for Cortex-Sparing 
High-Grade Glioma Treatment Plans,” AAPM Annual Meeting, Washington, D.C. *Best 
in Physics (Therapy)* 
6. K. Woods, D. Nguyen, A. Tran, V. Yu, M. Cao, K. Sheng (2015, July). “Comparison of 
Coplanar VMAT, Non-Coplanar VMAT, and 4π Treatment Plans,” AAPM Annual 
Meeting, Anaheim, CA. 
7. K. Woods, S. Boucher, B.M. Hegelich, V. Bashkirov, R. Schulte (2013, October). 
“Diagnostic Proton Computed Tomography Using Laser-Driven Ion Acceleration,” 
North American Particle Accelerator Conference, Pasadena, CA. 
 
INVITED TALKS 
A Double-Focused Sparse Orthogonal Collimator for Small Animal IMRT Using Rectangular 
Aperture Optimization. AAPM-SCC Norm Baily Award Meeting 1st place prize, May 2018. 
 1 
1 INTRODUCTION 
 According to the International Agency for Research on Cancer (IARC), over 18 
million new cancer cases were diagnosed worldwide in 20181. Of these cancer patients, it is 
estimated that over 50% can benefit from some form of radiotherapy2. With almost 10 
million cancer deaths worldwide in 20181, there is clearly a need for improved radiotherapy 
techniques to increase overall survival rates. However, the number of cancer survivors 
treated with radiation is increasing steadily and is projected to reach over 4 million in the 
United States alone by 20303, making the mitigation of long-term side effects of radiotherapy 
equally as important.  
 Technological advancements in radiation oncology have greatly improved the 
precision and conformity of radiotherapy techniques. Much of this is due to advancements 
in imaging, with new diagnostic imaging techniques enabling better tumor delineation and 
image-guidance allowing for smaller treatment margins and lower normal tissue toxicity4. 
Recent advances in magnetic-resonance (MR) guided radiotherapy offer significant 
improvements in soft tissue visualization, further expanding the realm of treatment 
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possibilities5,6. With this technology it is feasible to deliver highly conformal, potentially 
escalated doses and to implement more novel techniques such as adaptive therapy, 
advanced motion management, and spatial or temporal dose modulation. However, although 
we may have the technical capabilities, there are currently several factors limiting the full 
exploitation of innovative techniques necessary for achieving significant improvements in 
patient outcomes. 
1.1 4π Radiotherapy 
 One such limitation is the manual selection of largely coplanar beam angles used in 
clinical treatment planning. Although the use of noncoplanar beams has been shown to 
increase dose conformity and improve organ-at-risk (OAR) sparing7, the manual selection of 
highly noncoplanar angles is tedious and unintuitive. This is further complicated by the 
increased risk of collision between couch and gantry. The 4π radiotherapy framework was 
developed to address this problem, enabling the automated selection of highly noncoplanar 
beam angles that can be delivered on a conventional C-arm linear accelerator8. 4π 
radiotherapy has demonstrated significant potential for increased dose conformity and 
normal tissue sparing in the treatment of tumors in the liver8, lung9, head-and-neck10, 
prostate11,12, brain13, and spine14 when compared to conventional intensity modulated 
radiation therapy (IMRT) with manually selected beams or volumetric modulated arc 
therapy (VMAT). An individualized collision prediction model has also been developed to 
enable fully automated noncoplanar plan delivery15. 
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1.2 Preclinical Radiotherapy 
 Another limitation to the use of these novel treatment techniques is a lack of 
understanding of the underlying biological mechanisms. Much of this advancement has been 
driven by physics and engineering developments, and preclinical validation is needed to 
determine which strategies will actually improve patient outcomes.  Small animal models 
are the most practical and widely used preclinical research tool, and can help us gain a better 
understanding of cancer cell growth and radiation response16,17. These research findings, 
however, often cannot be replicated in human clinical trials due in large part to the 
discrepancy in irradiation techniques18-21.  
 Although the incorporation of image-guidance technology into small animal 
radiotherapy has greatly increased preclinical research potential, these systems are still not 
able to deliver IMRT, the clinical gold standard. IMRT requires inverse fluence map 
optimization and dose modulating hardware, both of which must be adapted for the small 
animal scale. The dynamic multileaf collimator (MLC) is used for dose modulation in clinical 
treatment, but due to its complexity previous attempts to miniaturize this device for the 
small animal scale have been relatively unsuccessful, as well as several other attempted dose 
modulation strategies22-25.  We have developed a simpler device, the sparse orthogonal 
collimator (SOC), better suited for small animal radiotherapy. Using a corresponding 
treatment planning system based on rectangular aperture optimization (RAO), we can create 
high quality small animal IMRT plans for delivery with the SOC. 
 4 
1.3 Overview 
 Preliminary studies will first be presented on the validation of 4π radiotherapy for 
specific treatment sites and the development of tools and techniques for dosimetric 
evaluation in preclinical radiotherapy research. Development and commissioning of the SOC 
treatment planning and delivery systems are then detailed. 
 Chapter 2 describes three planning studies in which the feasibility and advantages 
of 4π radiotherapy are evaluated for different applications. First, a version of the paper 
“Viability of noncoplanar VMAT for liver SBRT compared with coplanar VMAT and beam 
orientation optimized 4π IMRT” published in Advances in Radiation Oncology26 is presented. 
This study evaluates the plan quality, particularly dose conformity and normal liver sparing, 
for liver SBRT plans using standard coplanar VMAT, noncoplanar VMAT, and 4π plans with 
20 optimized noncoplanar static beams. Next, a version of the paper “Cochlea-sparing 
acoustic neuroma treatment with 4π radiotherapy”, also published in Advances in Radiation 
Oncology27, is presented. In this study, 4π radiotherapy is evaluated for its potential to spare 
dose to the cochlea in acoustic neuroma treatment and potentially reduce the risk of 
subsequent hearing loss. The third study is part of the paper “4π plan optimization for 
cortical-sparing brain radiotherapy” published in Radiotherapy and Oncology28. This work 
was performed in collaboration with researchers at the University of California San Diego, 
and investigates the ability of 4π radiotherapy to reduce the dose to the cortex in brain 
radiotherapy, consequently reducing the risk of cognitive decline post-treatment. 
 In Chapter 3, two projects related to preclinical radiotherapy dosimetry are 
presented. In the first, two types of mouse phantoms were developed for the evaluation and 
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standardization of the dosimetric accuracy of small animal irradiation techniques. These 
phantoms were sent to institutions across the country for irradiation, and the resulting 
dosimetry was analyzed using thermoluminescent dosimeters (TLDs), optically stimulated 
luminescent dosimeters (OSLDs), and radiochromic film dosimetry. Next, an anatomically 
accurate monkey phantom was developed for preclinical dosimetry. A flexible, 
straightforward phantom fabrication process was established using 3D printing methods 
with materials closely mimicking the radiological properties of tissue, lung, and bone. 
 Chapter 4 describes the development and commissioning of the SOC treatment 
planning system. The RAO algorithm is presented, with several planning experiments 
demonstrating its ability to create highly concave, complex dose distributions deliverable 
with the SOC. Beam commissioning data acquired on the X-RAD SmART Small Animal Image-
Guided Radiotherapy system at UCLA is presented, including output and off-axis factors, 
percent depth dose data, and field flatness. The incorporation of this data into the treatment 
system is described, as well as the implementation of post-optimization dose recalculation 
and aperture weighting reoptimization. This is a version of the paper “A Sparse Orthogonal 
Collimator for Small Animal Intensity Modulated Radiation Therapy, Part I: Planning System 
Development and Commissioning”, currently in submission29. 
 In Chapter 5, the complete design and fabrication process of the SOC hardware is 
detailed. SOC commissioning data is presented, including measurements of mechanical 
alignment, leaf transmission, penumbra, and leaf positioning accuracy and repeatability. The 
measured dose distributions from the plans described in Chapter 4 are presented, and the 
agreement between the measured and intended doses is evaluated. This is a version of the 
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paper “A Sparse Orthogonal Collimator for Small Animal Intensity Modulated Radiation 
Therapy, Part II: Hardware Development and Commissioning”, also currently in 
submission30. 
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2 4Π RADIOTHERAPY 
2.1 Viability of Noncoplanar VMAT for Liver SBRT 
Compared with Coplanar VMAT and Beam Orientation 
Optimized 4π IMRT26 
2.1.1 Introduction 
 Liver cancer is responsible for over 600,000 deaths each year, according to the 
American Cancer Society, making it a leading cause of cancer deaths worldwide. Although 
surgical resection is considered the primary treatment option for hepatocellular carcinoma 
and oligometastases, 80 to 90% of patients present with unresectable tumors31, which are 
treated with modalities including radiation therapy. Conventionally fractionated 
radiotherapy has proven ineffective to achieve local control32. Stereotactic body radiation 
therapy (SBRT), with the delivery of fewer high-dose fractions, is a more effective treatment 
for patients with eligible conditions33, which typically include inoperable liver tumors under 
the size of 6 cm and certain liver function criteria34. The success of SBRT is largely owed to 
the higher biological effective doses (BED) and normal tissue sparing afforded by improved 
dose conformity from recent advances in radiation physics31,35,36. 
 Volumetric modulated arc therapy (VMAT) is a practical and effective delivery 
technique for liver SBRT, and has demonstrated normal tissue sparing and dose conformity 
superior to coplanar intensity modulated radiation therapy (IMRT)37. Although the 
incorporation of noncoplanar beams has improved normal tissue sparing in liver IMRT 
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studies7,37,38, typical clinical VMAT liver plans are still coplanar, consisting of a pair of 
(clockwise and counterclockwise) arcs using collimators with 90˚ rotational offset. To gain 
dose conformity and liver sparing, manually selected noncoplanar VMAT has been clinically 
used but its benefit has not been quantified. Meanwhile, methods for the automatic selection 
of noncoplanar IMRT beams and optimized fluence maps have been developed for treatment 
sites including liver SBRT. Two separate groups have shown that by optimizing noncoplanar 
beam orientation selection, superior dosimetry to coplanar VMAT can be attained7,39. In this 
study, we refer to the beam orientation optimized noncoplanar IMRT plans as “4π static” 
because of the maximum of 4π steradian angles that can be used for noncoplanar beam 
orientation optimization. The useable angles are typically smaller than 4π due to collision 
concerns and couch pedestal occlusion40. Since the delivery efficiency of noncoplanar IMRT 
plans is considered lower than that of VMAT without the use of automation, a function 
unavailable to most clinics, one important question is whether manually selected 
noncoplanar VMAT, which is the only clinically available method to incorporate these arcs, 
can offer dosimetry superior to coplanar VMAT while maintaining the advantage of clinical 
availability and efficiency. The purpose of this study is therefore to quantify and compare 
the dosimetry of these planning methods for liver SBRT. 
2.1.2 Methods 
2.1.2.1 Coplanar VMAT Plans 
 Under institutional review board approval, treatment plans including CT, dose, and 
contours were obtained for 20 liver SBRT patients (Table 2-1).  These patients were treated 
with VMAT plans (RapidArc, Eclipse Treatment Planning System Version 10, Varian), 
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typically consisting of two full coplanar arcs (cVMAT) with 90° collimator angle offset. The 
few original plans that included one partial noncoplanar arc were re-optimized in Eclipse 
with two full coplanar arcs to set a uniform baseline. 
Table 2-1 Patient Data 
 Diagnosis 
Prescription 
Dose (Gy) 
Fractions 
PTV 
Volume 
(cm3) 
Normal Liver 
Volume (cm3) 
Liver 
Volume 
(cm3) 
1 Metastatic esophageal 
cancer 
60 5 53.3 1491.0 1544.5 
2 Metastatic squamous 
cell carcinoma 
60 5 64.9 2169.9 2234.7 
3 
Metastatic 
adenocarcinoma of 
the lung 
60 5 46.7 1194.2 1239.0 
4 Metastatic colorectal 
cancer 
60 5 35.6 1168.6 1187.5 
5 Metastatic colon 
cancer 
60 5 59.2 1404.7 1454.3 
6 Metastatic colorectal 
cancer 
50 5 123.0 1324.1 1447.1 
7 Metastatic uterus 
carcinosarcoma 
50 5 35.1 1768.8 1803.8 
8 Metastatic transitional 
cell from the kidney 
60 5 30.2 1241.2 1270.1 
9 Metastatic colon 
cancer 
50 5 179.0 1752.7 1909.4 
10 Hepatocellular 
carcinoma 
36 3 54.4 1133.4 1187.9 
11 Metastatic colon 
cancer 
60 5 88.4 1302.7 1391.1 
12 Metastatic prostate 
adenocarcinoma 
60 5 10.5 1442.7 1453.3 
13 Metastatic 
cholangiocarcinoma 
40 5 48.8 1837.0 1837.0 
14 Metastatic high-grade 
cholangiocarcinoma 
48 3 19.4 1027.0 1047.8 
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15 Cholangiocarcinoma 40 5 88.7 1787.0 1852.0 
16 Cholangiocarcinoma 40 5 67.0 2517.6 2577.3 
17 Cholangiocarcinoma 40 5 141.8 1809.6 1926.6 
18 Metastatic primitive 
germ cell tumor 
30 5 192.9 3342.8 3346.1 
19 
Metastatic gall 
bladder small-cell 
carcinoma 
60 5 109.4 1533.5 1616.2 
20 Metastatic bile duct 
adenocarcinoma 
50 5 57.3 1107.8 1148.6 
 
2.1.2.2 Noncoplanar VMAT Plans 
 These clinical plans were re-planned in Eclipse with 3 to 4 manually selected partial 
noncoplanar arcs (nVMAT), as shown in Figure 2-1 (middle), with collimator angle offsets 
between 45° and 135°. The average total arc length for the 20 nVMAT plans was 553°. These 
arcs were empirically chosen to maximize noncoplanar angles while avoiding collision. Each 
plan typically consisted of one arc with a 0° couch rotation, two arcs with an average couch 
rotation of ±21° (-40° to +35° range), and for a few patients with tumors located near the 
mid-sagittal plane, one arc with a nearly perpendicular couch kick (86° on average). The 
optimization objectives were set up to minimize dose to liver, kidneys, spinal cord, and 
stomach, with the highest priority placed on the normal liver dose. All plans were normalized 
to deliver 100% of the prescribed dose to 95% of the planning target volume (PTV), and PTV 
hot spots were limited to those of the respective coplanar plans. A source-to-axis distance 
(SAD) of 100 cm was maintained for all plans. 
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2.1.2.3 4π Static Plans 
 The first step in the 4π static optimization process, the details of which have been 
previously reported39, is to eliminate any beams out of the 1162 beam 4π static solid angle 
space that would cause collisions between the gantry and couch or patient. From the 
remaining beams, an integrated beam orientation and fluence map optimization is 
performed using a greedy column generation method41. Briefly, the remaining candidate 
beams were subdivided into 5 x 5 mm2 beamlets and the dose distribution matrices of each 
beamlet were calculated using collapsed-cone convolution/superposition codes and 6 MV x-
ray polyenergetic kernels with heterogeneity corrections. The dose calculation model was 
tuned to match 6 MV machine commissioning data. The dose calculation resolution was 2.5 
x 2.5 x 2.5 mm3. The first-order derivative of the quadratic cost function with each additional 
beam from the candidate pool was evaluated and the beam that contributed most was kept. 
 This process was iteratively performed until the desired number of beams was 
selected. Full fluence map optimization was performed after each beam selection. Although 
the cost function value did not converge, the dosimetric gains with more than 20 beams were 
modest. Considering a balance between plan deliverability and plan quality, in this study, 20 
beams were selected with the 4π static algorithm for each patient, such as those in Figure 
2-1 (right). The gantry and couch angles for each beam were imported into Eclipse to develop 
a clinically deliverable treatment plan using an identical dose calculation engine to the VMAT 
plans. The organ at risk (OAR) constraints, plan normalization, SAD, and PTV hotspots 
matched those described earlier for the nVMAT plans. 
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2.1.2.4 Additional notes on the optimization implementation 
 For each plan optimization, dose constraints were placed on the liver, kidney, spinal 
cord, and stomach. When necessary, additional optimization constraints were placed on 
other OARs such as the bowel or heart, depending on the location of the tumor. Although the 
constraints and penalties were initially the same for each, these parameters were adjusted 
throughout the optimization process in order to further reduce OAR doses for all techniques. 
Since plan optimization with Eclipse depends on both the sequence of the planning 
parameters used along with the process and the timing of when they are used, maintaining 
a single set of constraints and penalties generally would result in poorer plan quality. 
Instead, the objectives for each plan were pushed as hard as possible to reduce OAR doses, 
particularly to the normal liver, while maintaining acceptable PTV doses. The normal tissue 
objective was also used, with a 0.1 cm distance from target border, 99% start dose, 50% end 
dose, and 0.2 fall-off. Each plan was re-optimized until no further OAR dose reduction could 
be achieved without compromising PTV coverage (typically between two and four runs). 
 
Figure 2-1 Beam geometry comparison for a typical liver SBRT case. Beam orientation is shown for the 
coplanar VMAT plan (left), 3 to 4 noncoplanar partial arcs (center) and 20 noncoplanar, optimized beams 
(right). 
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2.1.2.5 Plan Comparison 
 The cVMAT, nVMAT, and 4π static plans were evaluated by comparing various 
metrics of normal tissue sparing. The minimum dose to 98% of the PTV (D98%) was 
compared between the three plans to evaluate any under-dosage to the target. The 
conformity of each plan was evaluated by the conformation number (CN), defined by van’t 
Riet et al as 
𝐶𝑁 =
𝑇𝑉𝑅𝐼
𝑇𝑉
×
𝑇𝑉𝑅𝐼
𝑉𝑅𝐼
 , 
Equation 2-1 
where TVRI is the target volume covered by the prescription isodose, TV is the target volume, 
and VRI is the volume of the prescription isodose42. R50, defined as the ratio of the 50% 
isodose volume to the PTV, was used to evaluate the dose gradient outside the PTV. The 
homogeneity index (HI) was also calculated as 1+(D2% - D98%)/(Prescription Dose). The 
normal liver volume receiving >15 Gy (VL>15) was quantified to assess normal tissue dose, 
as were the mean and maximum doses to OARs.  
 A radiobiological modeling study was performed to compare the probabilities of 
tumor control, normal tissue complication, and patient survival. The tumor control 
probability (TCP) was first calculated for each plan. Because TCP calculation parameters 
vary widely between studies and for different tumor types43,44, and because a variety of 
tumor origins were included in this study, high tumor radioresistance was assumed for the 
parameter selection (α = 0.2 Gy-1, α/β = 10 Gy) for a conservative TCP estimate. The Kutcher-
Burman dose-volume histogram (DVH) reduction scheme45 was used to calculate the normal 
liver effective volume (Veff), the percentage of the normal liver volume that, if irradiated 
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uniformly to the prescription dose, would give the same normal tissue complication 
probability (NTCP) as the non-uniform dose distribution. The effective volume was then 
used to calculate the normal liver NTCP using the Lyman model46. The Lyman-Kutcher-
Burman (LKB) NTCP model parameters from Dawson et al were used (TD50 = 45.8 Gy 
[metastases], TD50 = 39.8 Gy [primary tumors], n = 0.97, m = 0.12)47. Since these parameters 
were obtained from fractionated treatment plans, the SBRT plans in this study were 
normalized to 1.5 Gy per fraction using α/β = 2.5 Gy48. 
2.1.2.6 Dose Escalation 
 The prescription dose for each plan was escalated (or reduced) to the maximum 
tolerable dose (MTD) yielding a normal liver NTCP below the desired limit. The number of 
fractions for the clinical plans were maintained, with an escalated dose per fraction. In this 
study, MTDs for NTCP limits of 1%, 5%, and 10% were calculated.  The biological effective 
dose (BED) for each MTD was determined by 
𝐵𝐸𝐷 = 𝑁𝑑 +
𝑁
𝛼 𝛽⁄
𝑑2 −
𝑙𝑛2
𝛼𝑇𝑑
𝑇 , 
Equation 2-2 
with number of fractions N, dose per fraction d, total treatment time T, α = 0.01, α/β = 15, 
and tumor doubling time Td = 120 days from Tai et al49. The survival model developed by Tai 
et al was used to predict the survival rates (SR) for each plan based on the BED: 
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𝑆𝑅(𝐷, 𝑑, 𝜏) = 1 −
1
√2𝜋
∫ 𝑒−
𝑥2
2 𝑑𝑥 
𝑡
−∞
, 
𝑡 =
𝑒
−[𝛼(1+
𝑑
𝛼 𝛽⁄
)𝐷−𝛾𝑇−(𝛾(𝜏−𝑇))
𝛿
]
− 𝐾50 𝐾0⁄
𝜎𝑘 𝐾0⁄
 
Equation 2-3 
where D is the prescription dose, τ is the elapsed time since treatment, δ describes the tumor 
growth rate, K0 is the initial number of tumor clonogens, K50 is the critical number of tumor 
clonogens corresponding to death in 50% of patients, σk is the Gaussian width for the critical 
clonogen number distribution, and γ = ln2/Td. The fitting parameters from Tai et al are K50/K0 
= 2.03, σk/K0 = 0.65, and δ = 0.249. Survival fractions at 1, 2, 3, and 4 years were calculated 
for each plan before and after dose escalation. 
2.1.3 Results 
2.1.3.1 Plan Comparison 
 The average dose statistics for each plan type, using paired, 2-tailed t-tests, are given 
in Table 2-2. On average, the nVMAT plans delivered higher kidney doses than the cVMAT 
plans and lower doses to the other OARs, but the only statistically significant difference was 
an increased V50%. However, there were large improvements with 4π static compared to 
both VMAT techniques.  The mean dose to the normal liver was significantly lower with the 
4π static plan, and the liver volume receiving >15 Gy was reduced from the cVMAT and 
nVMAT plans by 79.8 cm3 and 74.8 cm3, respectively (>32%). Although nVMAT enabled 
reductions in maximum stomach and spinal cord doses (compared to cVMAT) of 
approximately 2% and 14%, respectively, 4π static reduced these doses by 32% and 40%. 
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The HI and CN values were similar for all plans.  The individual dosimetric parameter 
comparison is shown in Figure 2-2. Consistent reduction in the R50 from cVMAT to 4π static 
was observed for all patients and the reduction is correlated to that of liver V15 and mean 
liver dose. In comparison, R50 of nVMAT slightly increased from cVMAT, indicating no 
improvement in the dose compactness. 
Table 2-2 Average dose statistics for coplanar VMAT, noncoplanar VMAT, and 4π plans for all 20 
patients (HI: homogeneity index, CN: conformation number) 
 
Plan 
Type 
Organ-At-Risk Doses (Gy) 
L Kidney 
Mean 
R Kidney 
Mean 
Normal 
Liver 
Mean 
Stomach 
Max 
Cord 
Max 
Body 
Mean 
cVMAT 1.42* (2.4) 2.04 (2.4) 7.07* (2.6) 11.15 (6.7) 6.69* (3.2) 1.51* (0.6) 
nVMAT 1.46* (2.1) 2.09 (2.5) 6.97* (2.8) 10.95* (10.0) 5.74* (4.0) 1.51* (0.6) 
4π 0.82 (1.2) 1.70 (1.4) 6.01 (2.3) 7.58 (6.3) 4.00 (3.7) 1.46 (0.6) 
 
PTV D98% 
(Gy) 
VL>15 
(cm3) 
V50% 
(cm3) 
R50 HI CN 
cVMAT 49.62* (9.6) 
233.7* 
(120.8) 
271.5** 
(185.6) 
3.66* (0.4) 0.11 (0.03) 0.94 (0.03) 
nVMAT 49.59 (9.7) 
228.7* 
(122.3) 
287.5** 
(213.4) 
3.77* (0.5) 0.10 (0.02) 0.93 (0.04) 
4π 49.42 (9.7) 
153.9 
(84.5) 
210.8 
(146.4) 
2.82 (0.3) 0.11 (0.03) 0.93 (0.03) 
*Significantly different from 4π with p<0.05 (paired, 2-tailed t-test). 
**Significantly different from 4π and other VMAT plan type with p<0.05 (paired, 2-tailed t-test). 
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Figure 2-2 Individual patient dosimetric results comparison between cVMAT, nVMAT, and 4π static. 
 
 These reductions in OAR dose are evident in the DVHs in Figure 2-3 (top). 
Additionally, the 4π static technique reduced the 50% dose spillage volume by >22% 
compared to both VMAT plans. The major reduction in 50% isodose volume with the 4π 
static technique is evident in the dose washes in Figure 2-3 (bottom). Although the dose 
washes show less low dose spillage for the nVMAT plan than the cVMAT plan, the isodose 
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volume above 15 Gy is very similar. There was a statistically significant difference between 
the mean cVMAT and 4π static PTV D98% doses, but only by 0.2 Gy.   
 
Figure 2-3 (Top) Dose-volume histograms for a typical liver SBRT case. (Bottom) Dose color washes 
for each plan type. The orange contours represent the PTV volume and the blue represent the 50% 
isodose lines. 
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 The average TCP values (calculated with the LKB model), given in Table 2-3, were 
very similar for nVMAT and cVMAT plans and slightly (~1.1%) lower for 4π static. Although 
the optimization constraints on the maximum PTV dose were relaxed, 4π static plans still 
tend to result in more homogenous PTV doses, as seen in the DVH in Figure 2-2 (top), and 
slightly lower TCP.  
Table 2-3 Biological modeling parameter results for cVMAT, nVMAT, and 4π plans for all 20 patients 
(standard deviation in parentheses) 
 TCP (%) Veff (%) NTCPa (%) 
cVMAT 7.37 (11.5) 13.79* (5.2) 5.29 (18.8) 
nVMAT 7.40* (11.1) 14.00* (5.9) 6.22 (22.2) 
4π 6.25 (9.7) 11.63 (4.4) 1.65 (6.3) 
aThe mean NTCP is drastically increased by two outlying patients, without which the mean NTCP 
values are 0.06%, 0.53%, and 0.02% for cVMAT, nVMAT, and 4π, respectively. 
*Significantly different from 4π plans with p<0.05 (paired, 2-tailed t-test). 
 
 The average normal liver effective volume was very similar for the VMAT plans, but 
was significantly reduced with 4π static by >15%. The resultant NTCP was therefore also 
much lower, with reductions of 69% from cVMAT and 73% from nVMAT. 
2.1.3.2 Dose Escalation 
 The results of the dose escalation are given in Table 2-4. For every NTCP limit, 4π 
static enabled significantly higher average MTDs than both cVMAT and nVMAT. The 
escalated doses for 4π static were approximately 20% and 14% higher than those for cVMAT 
and nVMAT, respectively. The corresponding BEDs for 4π static were higher than cVMAT 
and nVMAT for every NTCP limit by about 39% and 19%, respectively, with a statistically 
significant difference between 4π static and cVMAT at the 5% level (paired, 2-tailed t-test). 
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The average MTD and BED for nVMAT were higher than cVMAT for every NTCP limit, but not 
statistically significant at the 5% level. 
Table 2-4 Dose escalation based on the normal liver effective volume and desired normal liver LKB 
NTCP for all 20 patients (standard deviation in parentheses) 
 
1% NTCP 5% NTCP 10% NTCP 
MTD (Gy) BED (Gy) MTD (Gy) BED (Gy) MTD (Gy) BED (Gy) 
cVMAT 
76.80* 
(27.6) 
170.40* 
(97.8) 
85.51* 
(30.7) 
202.70* 
(117.6) 
90.14* 
(32.4) 
220.94* 
(129.0) 
nVMAT 
80.63* 
(37.7) 
198.32 
(177.7) 
89.76* 
(41.6) 
236.78 
(215.5) 
94.65* 
(43.8) 
258.67 
(237.4) 
4π 
91.98 
(36.2) 
235.80 
(164.8) 
102.43 
(40.3) 
281.91 
(199.8) 
107.99 
(42.5) 
308.08 
(219.8) 
*Significantly different from 4π plans with p<0.05 (paired, 2-tailed t-test). 
 
 The average survival fractions at 1, 2, 3, and 4 years for each NTCP limit (1%, 5%, 
and 10%) showed a statistically significant increase for the 4π static plans compared to both 
VMAT plans, as shown in Figure 2-4. These improvements were most significant for the 4π 
static four year survival fraction, which was over 7% higher than both VMAT plans at the 
10% and  5% NTCP limits and over 9% higher at the 1% NTCP limit. Even for conservative 
treatments allowing for only a 1% probability of liver complications, the 4π static technique 
enabled an average four year survival fraction of 86%. This increased to 93% when a 10% 
NTCP was tolerated.  
2.1.3.3 Delivery Time 
 The delivery time for two arc cVMAT for SBRT treatment was estimated as five to 
seven minutes. The time increased by an additional one to three minutes for nVMAT, 
depending on whether remote couch rotation was used. Delivery of the 4π treatment with 
 21 
20 beams can take 45 minutes with manual couch rotation and translation. However, a 
significant portion of this time is used by the therapist to enter and exit the shielded vault. 
Consequently, the time can be reduced to approximately 12 minutes with automated 
delivery40, in line with the nVMAT delivery time. 
 
Figure 2-4 Average survival predicted with the model from Tai et al49 for the maximum tolerable 
doses yielding 1%, 5%, and 10% normal liver NTCPs. All fractions for nVMAT and cVMAT were 
significantly different than 4π static at the 5% significance level (paired, 2-tailed t-test). 
2.1.4 Discussion 
 The success of SBRT is largely attributed to the improved physical dose conformity 
enabled by recent advances in radiation therapy techniques, including intensity modulated 
radiation therapy, image-guided radiation therapy, and volumetric modulated arc therapy. 
A previous study showed that tumor local control can benefit from further dose escalation35, 
but is limited by normal tissue toxicity. 
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 Experience from intracranial radiosurgery suggests that an effective way to achieve 
a steeper dose gradient outside the tumor is by adding noncoplanar beams and arcs50. The 
usefulness of noncoplanar beams in SBRT has been far less clear. R50 has been commonly 
used to evaluate the dose compactness in SBRT treatment51, the minimization of which leads 
to more effective SBRT52.  Lung Radiation Therapy Oncology Group protocols53 recommend 
using either noncoplanar static or coplanar arc beams to achieve the R50 dosimetric goal. Lim 
et al54 showed that compared with coplanar plans, lower R50 could be achieved in 81% of 
patients when noncoplanar beam arrangement was employed. However, in a different lung 
study, no dosimetric improvements were found comparing coplanar and noncoplanar IMRT 
plans55.  In the case of liver radiotherapy, it was found that the advantage of using 
noncoplanar beams can be matched by coplanar plans with a large number of beams56. 
Noncoplanar VMAT has been used on an ad hoc basis in liver SBRT37 with the expectation 
that these arcs should improve normal organ sparing without quantification of the 
dosimetric improvement. 
 In this study, we compared three clinically deliverable planning methods for liver 
SBRT. Our study shows that the incorporation of this type of arrangement of noncoplanar 
VMAT arcs offered modest dosimetric gains over coplanar VMAT. However, by fully utilizing 
the freedom of the noncoplanar beam geometry solution space and automated beam 
orientation selection, the 4π static technique achieved major reductions in the dose to OARs, 
particularly the normal liver, stomach, and spinal cord, as well as a much more compact dose 
distribution. 
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 There are several reasons for the minimal plan quality improvement from nVMAT 
over cVMAT. First, in practice, the number of VMAT arcs is limited. Due to the continuity of 
the arcs, large noncoplanar angles are prohibited to avoid collision. This is different from 
intracranial stereotactic radiation surgery, where a large noncoplanar beam solution space 
can be nearly uniformly sampled and included. It has been shown that the inclusion of small 
noncoplanar arc angles in a rotational IMRT system does not significantly improve the plan 
quality57.  Second, selection of noncoplanar arcs is unintuitive to the planner. It is difficult, if 
not impossible, for a human operator to optimally select segments of noncoplanar arcs, 
considering the freedoms of arc lengths and locations.  One way to overcome this limitation 
is by optimizing the noncoplanar arc selection. However, a method to globally search the 
noncoplanar arc trajectories, or “4π arc”, is currently unavailable. Papp et al58 reported a 
noncoplanar arc optimization method based on static beam orientation optimization and 
then using these beams to anchor noncoplanar segments. However this method does not 
promise that arcs between the anchoring beams are optimal. Furthermore, this method 
would result in arcs that require simultaneous couch and gantry rotation and are 
undeliverable in the clinical mode. Both limitations are effectively overcome using 4π static 
planning, where the collision-free beam geometry solution space is individually mapped and 
the beam orientations are optimized.  Therefore, even though nVMAT is currently available 
and more efficient to deliver, it is not a reasonable substitution for 4π static. 
 A major difference between the current study and the previously published report 
of using 4π static for liver SBRT39 is that the liver SBRT plans are generated in Eclipse using 
identical dose calculation engine to ensure an unbiased comparison. Compared to the 
previous study, the liver VL>15 was further reduced by an additional ~30 cm3 to 80 cm3. This 
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increased normal tissue sparing is crucial for liver SBRT because it enables escalation of the 
prescription dose to the PTV without further complications from high doses to normal tissue. 
Our dose escalation study showed that for the same normal liver complication probability, 
prescription doses delivered with the 4π static technique could be escalated 20% higher 
than cVMAT plans and 14% higher than nVMAT plans, leading to significant increases in 
predicted survival fractions.  
 Improved liver tumor motion management can be combined with 4π static 
radiotherapy for additional dosimetric gains, but the gains may be less significant. For 
example, Velec et al59 showed that by reducing the PTV volume using the mean respiratory 
position, the isotoxicity PTV dose can be escalated by 4 Gy, which is moderate compared to 
the dose escalation using 4π static. 
2.1.5 Conclusions 
 4π static radiotherapy using optimized noncoplanar beams significantly reduces 
normal liver doses, enabling safe tumor dose escalation. Despite its clinical availability, 
VMAT using noncoplanar arcs is not a viable replacement for 4π static radiotherapy for 
compact dose liver SBRT. 
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2.2 Cochlea-Sparing Acoustic Neuroma Treatment with 
4π Radiation Therapy27 
2.2.1 Introduction 
 Acoustic neuroma, also known as vestibular schwannoma, is a benign brain tumor 
arising from the eighth cervical nerve. There are 2000 to 3000 new cases of benign acoustic 
neuroma in the United States each year, approximately 25% of which are treated with 
radiation therapy60. Due to its benign nature, the prognosis for acoustic neuroma patients is 
typically very good, and with proper surveillance and treatment, no decrease in lifespan is 
expected. Therefore, the long term post-treatment toxicity must be heavily weighted for 
these patients. Although the complication rates are much lower than with surgery61-63, some 
patients do experience radiation-induced side effects following treatment. Up to 40% of 
patients may experience middle ear side effects such as otitis media during treatment64, 
which can cause tinnitus, dizziness, and pain. Almost half of patients may also experience 
some degree of sensorineural hearing loss (SNHL), which continues to worsen for years after 
treatment65-71.  
 There is evidence suggesting a correlation between the dose to the cochlea and the 
degree of hearing loss observed after radiation therapy for tumors in the head and neck 
region72-76. For acoustic neuroma patients treated with fractionated stereotactic 
radiotherapy, a study by Thomas et al showed that the minimum and maximum cochlear 
doses, as well as the percentage of the cochlea receiving 50%, 80%, and 90% of the 
prescription dose were all strongly predictive of subsequent hearing deterioration77. For 
stereotactic radiosurgery (SRS), significantly better hearing preservation was observed by 
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Kano et al when the dose to the central cochlea was kept below 4.2 Gy78. Timmer et al also 
demonstrated a correlation between the maximum cochlear dose and the extent of hearing 
loss in acoustic neuroma patients treated with Gamma Knife radiosurgery79.  
 In addition to hearing loss, many acoustic neuroma patients experience cranial 
neuropathy following radiation therapy. In a study of 149 cases of acoustic neuroma 
radiosurgery, Foote et al found that the maximum dose to the brainstem was the most 
significant predictor of the incidence of facial, trigeminal, or any other type of neuropathy 
after treatment80. Therefore, the sparing of dose to the brainstem must also be a high priority 
for these patients.  
 However, adequate radiation doses must still be delivered in order to achieve long-
term tumor control. A large Gamma Knife patient cohort established that a median single 
fractional dose of 13 Gy to the tumor margin (50% isodose) is necessary for local control67. 
This dose prescription typically results in maximum doses of 26 Gy for Gamma Knife plans, 
which may not always be safely deliverable81, particularly for larger tumors. Although 12 to 
13 Gy is also the standard prescription dose for linac-based single fraction acoustic neuroma 
treatment, these plans follow different prescription conventions (typically 100% of the 
prescription dose to 95-100% of the target volume) and result in more homogeneous dose 
distributions with lower maximum doses. 
 Therefore, to reduce the risk of hearing loss and other normal tissue complications 
following treatment while also delivering an adequate dose for maximal tumor control, 
highly conformal dose distributions are needed that can better spare the surrounding 
normal tissue. The dosimetry of Gamma Knife has been compared to conformal and dynamic 
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arcs using linacs for acoustic neuroma treatment82. Although the Gamma Knife dose was 
slightly more conformal (by 2%), the maximal dose was also much higher. This may help 
local control but can increase the risk of hearing loss and other neurological side effects since 
the intracanalicular component of the cochlear nerve, the cochlear ramus of the internal 
auditory artery, and the facial nerve all traverse the target volume83. Another advantage of 
linac-based treatment is that the treatment can be fractionated for larger tumors. A clinically 
relevant question is whether recent advances in treatment planning techniques can be used 
to further improve linac plans. 4π radiotherapy, with optimized noncoplanar beam 
orientations, has been shown to significantly reduce normal tissue doses in the liver, 
prostate, brain, lung, and head and neck9,11,39,84. The aim of this study was to determine 
whether 4π can also produce superior dosimetry for acoustic neuroma treatment, 
potentially providing better sparing of the cochleae and reducing the risk of radiation-
induced complications such as hearing loss. 
2.2.2 Methods 
2.2.2.1 Clinical plans 
 Thirty patients previously treated with radiation therapy for benign acoustic 
neuroma were included in this study, and their computed tomography images, plan, dose, 
and contours were obtained (Table 2-5). Fourteen of these patients were treated with single-
fraction SRS with prescription doses of 12 to 13 Gy. Six patients received stereotactic 
radiation therapy (SRT) with 5 fractions of 5 Gy each. Ten patients received intensity 
modulated radiation therapy (IMRT) with 28 to 30 fractions of 1.8 Gy each. Static IMRT 
beams (7-11 beams) were used for 13 patients (IMRT), dynamic conformal arcs (4-5 partial 
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noncoplanar arcs) were used for 11 patients (DCAT), and volumetric-modulated arcs (2 full 
coplanar arcs or 2-4 noncoplanar partial arcs) were used for 6 patients (VMAT). 
Table 2-5 Patient data 
 Rx dose 
(Gy) 
Fractions 
Plan 
type 
PTV 
volume 
(cm3) 
 Rx dose 
(Gy) 
Fractions 
Plan 
type 
PTV 
volume 
(cm3) 
1 12 1 DCAT 0.5 16 25 5 IMRT 1.07 
2 12 1 IMRT 5.48 17 25 5 IMRT 2.45 
3 12 1 IMRT 2.7 18 25 5 VMAT 8.12 
4 12 1 DCAT 1.66 19 25 5 IMRT 0.24 
5 12 1 DCAT 3.33 20 25 5 IMRT 0.17 
6 12 1 DCAT 2.75 21 50.4 28 VMAT 6.3 
7 12 1 IMRT 0.74 22 50.4 28 VMAT 35.81 
8 12 1 DCAT 2.79 23 50.4 28 IMRT 17.29 
9 12 1 IMRT 2.54 24 50.4 28 DCAT 0.35 
10 12 1 DCAT 2.24 25 50.4 28 DCAT 2.42 
11 12 1 IMRT 3.1 26 50.4 28 DCAT 0.92 
12 12 1 IMRT 5.23 27 50.4 28 VMAT 10.87 
13 12 1 DCAT 2.65 28 50.4 28 IMRT 2.78 
14 13 1 DCAT 1.31 29 50.4 28 VMAT 13.58 
15 25 5 IMRT 2.54 30 54 30 VMAT 23.22 
(DCAT: dynamical conformal arc therapy; IMRT: static intensity modulated radiation therapy; VMAT: 
volumetric-modulated arc therapy) 
 
 The plans were created using the machine parameter file for a Novalis Tx machine 
equipped with a 0.25 cm high-definition multileaf collimator. The dose calculation resolution 
was 2 mm using the Analytical Anisotropic Algorithm, Version 10.0.28. The treatment 
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regimen was determined on the basis of tumor size and achievable organ-at-risk (OAR) 
sparing. Examples of the beam orientations for these plans are shown in Figure 2-5. The 
brainstem, chiasm, cochlea (one or both, depending on the tumor location), eyes, lenses, and 
optical nerves were included as critical organs for all plans. 
2.2.2.2 4π plans 
 4π plans were made for each patient using the optimization process previously 
published39,41. The optimization process started with a pool of 1162 candidate beams making 
up the 4π solid angle space, each with a separation of 6°. A computer-assisted design model 
of the Varian TrueBeam system, along with a 3-dimensional patient model, was used to 
detect any potential collisions between the gantry and the couch or patient.  
 After these beams were eliminated, the dose was calculated for 5 x 5 mm2 beamlets 
using convolution/superposition with a 6 MV polyenergetic kernel. A greedy column 
generation method was then used to perform an integrated beam orientation and fluence 
map optimization41. The objective function includes manually-tuned parameters for the 
priority and weighting of each OAR, which were set to penalize dose to the cochlea and other 
critical organs while maintaining a homogeneous dose to the planning target volume (PTV). 
A final beam count of 20 was chosen to fully exploit the noncoplanar space while maintaining 
reasonable deliverability, as shown by a prospective patient study85.  
 Next, using the optimized beams, fluence map optimization and dose calculation 
were performed again in Eclipse with parameters that were identical to those of the clinical 
plans for an unbiased comparison. The planning goal was to match the PTV coverage of the 
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clinical plans while reducing the dose to the cochleae and reducing or maintaining the doses 
to all other OARs. 
 
Figure 2-5 Examples of typical beam orientations for the clinical plans with 7 to 11 static beams 
(left), clinical plans with 2 to 5 arcs (middle), and 4π plans with 20 static beams (right). From Table 
2-5, these are patients 16, 4, and 1, respectively. 
 
2.2.2.3 Plan comparison 
 The 4π and clinical plans were compared on the basis of their PTV coverage and 
normal tissue sparing, specifically of the cochleae. The mean and maximum doses to the 
cochleae and all other OARs were compared for all plans. The volume receiving 50% of the 
prescription dose (V50%) was calculated to evaluate the dose spillage for each plan. To 
evaluate dose conformity, R100 (the ratio of the 100% isodose volume to the PTV) was 
compared, along with the van’t Riet conformation number (CN)42, defined as 
𝐶𝑁 =
𝑉𝑇,𝑅𝑥
𝑉𝑇
×
𝑉𝑇,𝑅𝑥
𝑉𝑅𝑥
 , 
Equation 2-4 
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where 𝑉𝑇 is the target volume, 𝑉𝑇,𝑅𝑥  is the volume of the target receiving a dose equal to or 
greater than the prescription dose, and 𝑉𝑅𝑥  is the total volume receiving the prescription 
dose. The homogeneity index (HI) was also calculated as  
𝐻𝐼 = 1 +
(𝐷2% − 𝐷98%)
𝐷𝑅𝑥
 
Equation 2-5 
where 𝐷𝑅𝑥 is the prescription dose and 𝐷2% and 𝐷98% are the minimum doses to 2% and 
98% of the PTV volume. 
 Radiobiological modeling was also used to predict the tumor control probability 
(TCP) and the normal tissue complication probability (NTCP) for SNHL. The definition of 
SNHL differs between studies but is typically considered a loss of at least 10 to 20 dB in one 
or more frequencies. Because hearing function has been shown to continue deteriorating 
over long follow-up times68, the SNHL NTCP at both 3 years and 5 years post-treatment was 
calculated for each plan.  
 The TCP was calculated using the Poisson-based model with the parameters shown 
in Table 2-6. The cochlea effective volume (Veff) was calculated with the Kutcher-Burman 
dose volume histogram reduction scheme, which estimates the volume of the cochlea which, 
if homogenously irradiated to the prescription dose, would result in the same NTCP as the 
actual inhomogeneous dose distribution86. This effective volume was then used to predict 
the NTCP values for the cochlea with the Lyman model46, using the parameters in Table 2-6. 
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Table 2-6 TCP and NTCP model parameters 
Model Parametera TCP 
SNHL NTCP 
(3 years) 
SNHL NTCP 
(5 years) 
α/β 2.4 Gy 2 Gy 2 Gy 
TCD50 27 Gy - - 
TD50 - 31.5 Gy 19.25 Gy 
γ50 1.5 0.71 0.46 
n - 0.83 0.83 
aα/β: ratio of the linear and quadratic terms of the organ-specific dose response curve; TCD50: tumor 
dose to achieve 50% TCP; TD50: whole organ dose resulting in 50% NTCP; γ50: slope of sigmoidal 
dose response curve at 50% TCP/NTCP; n: volume-effect parameter. (TCP: tumor control probability; 
SNHL: sensorineural hearing loss; NTCP: normal tissue complication probability) 
 
 All model parameters were selected on the basis of published clinical data on the 
relationship between treatment outcomes (tumor control and complication rates) and dose 
delivered to the tumor and cochleae68-71. Since the fractionation schemes varied widely 
among patients in this study, all plan doses were normalized to a reference dose of 2 Gy per 
fraction for radiobiological modeling. 
2.2.2.4 Dose escalation 
 Although excellent local control rates have been reported for acoustic neuroma 
treated with SRS and SRT, the control rates decrease in long-term follow up, particularly for 
larger tumors87,88. Therefore, there may be benefits to dose escalation if normal tissue 
complication rates remain low. A dose escalation study was performed to evaluate whether 
4π radiotherapy could achieve higher tumor control rates without increasing the risk of 
hearing loss for acoustic neuroma patients. The prescription doses for each plan were 
escalated until the plans achieved TCP values of 99.5%. The NTCP values for SNHL at 3 and 
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5 years post-treatment were then calculated for the escalated dose distributions and 
compared for the clinical and 4π plans. 
2.2.3 Results 
2.2.3.1 Plan comparison 
 The OAR doses and conformity measures for both plan types are given in Table 2-7 
and Figure 2-6. The mean cochlear dose was significantly reduced with 4π from 6.29 Gy to 
4.25 Gy for SRS plans, from 11.20 Gy to 8.00 Gy for SRT plans, and from 30.88 Gy to 20.93 Gy 
for IMRT plans. The maximum cochlear dose was also significantly reduced by 1.58 Gy 
(20%), 2.2 Gy (15%), and 7.1 Gy (18%) for SRS, SRT, and IMRT, respectively.  
 In addition, there was significant sparing of the brainstem with 4π, which reduced 
the mean and maximum doses by 18% and 7%, respectively. These reductions were 
achieved with a steeper dose gradient around the target, as illustrated by the dose wash in 
Figure 2-7. The mean and maximum doses to the chiasm were also 39% and 38% lower, 
respectively, for the 4π plans than for the clinical plans. The mean doses to the eyes, lenses, 
and optical nerves were reduced by 19% to 56% on average with 4π.  
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Table 2-7 OAR doses and conformity measures for both plan types 
Plan Type 
Average OAR Doses (Gy) 
V50% 
(cm3) 
PTV 
HI 
van’t 
Riet 
CN Brainstem Chiasm 
Cochleae 
SRS SRT IMRT 
Clinical 
Mean 6.61 2.12 6.29 11.20 30.88 
25.23 0.92 0.69 
Max 20.03 3.27 8.05 14.92 38.79 
4π 
Mean 5.41* 1.30* 4.25* 8.00* 20.93* 
24.85 0.93 0.73 
Max 18.59* 2.04 6.47* 12.72* 31.74* 
*Statistically significant difference from the clinical plans (2-tailed t-test, p<0.05) 
(CN: conformation number; HI: homogeneity index; max: maximum; V50%: volume receiving 50% 
of the prescription dose) 
 
Figure 2-6 Mean (top) and maximum (bottom) doses to the cochlea (SRS, SRT, and IMRT groups), 
brainstem, and chiasm with the 4π plans (red) and clinical plans (blue). All differences between the 
4π and clinical plans were statistically significant (2-tailed t-test, 5% significance level), except the 
maximum dose to the chiasm. 
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 The conformity measures were essentially the same between the clinical and 4π 
plans. The average V50% was 0.38 cm3 lower for the 4π plans than for the clinical plans. The 
4π plans were also able to maintain similar PTV coverage despite the major reductions in 
OAR doses, as illustrated in the dose volume histogram shown in Figure 2-8. The average 
R100 ratio was better for the 4π plans (1.32 vs 1.41) as well as the van’t Riet conformation 
number (0.73 vs 0.69). There was also a statistically significant increase in the PTV 
homogeneity index with 4π (0.93 vs 0.92). The total monitor units for each plan were, on 
average, 2248 for the 4π plans and 1561 for the clinical plans.  
 4π consistently improved the cochlea sparing compared with IMRT, DCAT, and 
VMAT patient subcohorts. The mean cochlea dose was reduced by 32.2%, 26.8%, and 35.1%, 
respectively. The maximum cochlea dose was reduced by 19.4%, 11.3%, and 21.3%, 
respectively. 
 
Figure 2-7 Dose color wash for a patient (patient 3 in Table 2-5) who was treated to a prescription 
dose of 12 Gy in a single fraction. Structures: PTV (blue), brainstem (green), and cochlea (red). 
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 The results of the radiobiological modeling study are given in Table 2-8. Although 
the difference was statistically significant, the TCP was only 0.3% higher for the clinical plans 
than for the 4π plans. This difference can be explained by the significantly greater hotspots 
within the PTV for the clinical plans because all plans were normalized for the same target 
coverage. The estimated TCP is consistent with clinical reports, in which prescription doses 
of at least 12 Gy for SRS and 50 Gy for IMRT yielded TCP values of >90%68-71. All NTCP 
predictions for SNHL were significantly higher for the clinical plans than for the 4π plans. 
The average NTCP was 10.0% higher for the clinical plans at 3 years and 18.4% higher at 5 
years post-treatment. 
Table 2-8 Results of the radiobiological modeling and dose escalation study 
Plan 
Type 
Average 
TCP 
Average SNHL NTCP 
Average 
Escalation Factor 
Escalated SNHL NTCP 
3 years 5 years 3 years 5 years 
Clinical 
95.7 ± 
0.9% 
40.8 ± 
5.9% 
61.7 ± 
10.8% 
1.162 ± 0.02 
43.4 ± 
6.3% 
64.7 ± 
11.1% 
4π 
95.4 ± 
0.9%* 
30.8 ± 
5.3%* 
43.3 ± 
11.2%* 
1.166 ± 0.02* 
32.6 ± 
5.5%* 
46.4 ± 
11.3%* 
*Statistically significant difference from the clinical plans (2-tailed t-test, p<0.05) 
(TCP: tumor control probability; SNHL: sensorineural hearing loss; NTCP: normal tissue complication 
probability) 
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Figure 2-8 Dose volume histograms (solid line: clinical plan; dashed line: 4π plan) for one of the 
patients who received SRS in this study (patient 2 in Table 2-5) with a prescription dose of 12 Gy. 
2.2.3.2 Dose escalation 
 To achieve a TCP of 99.5%, the prescription doses had to be escalated by a factor of 
approximately 1.16 on average for both plan types. After dose escalation, the probabilities of 
post-treatment SNHL at 3 and 5 years were once again significantly lower for the 4π plans, 
by 10.8% and 18.3%, respectively. The average NTCP for the escalated 4π plans was 8.2% 
lower than the normal (non-escalated) clinical plans at 3 years post-treatment, and 15.4% 
lower at 5 years.  
2.2.4 Discussion 
 Although normal tissue complications are a concern for every patient receiving 
radiation therapy, these risks must be weighted even more heavily for the treatment of 
benign tumors such as acoustic neuroma. The majority of these patients will have an 
unaffected life expectancy, and any radiation-induced side effects could have a lasting impact 
 38 
on quality of life that competes with the benefits of treatment. In addition, acoustic neuroma 
is a highly treatable disease. Therefore, despite high treatment success rates, technological 
improvement should not stop until 100% local control is achieved because uncontrolled 
tumor growth may ultimately compromise patient hearing and other neurological functions. 
While excellent local control (>98%) can be achieved with surgical resection, this treatment 
option carries significant risks in addition to hearing loss. Over 20% of surgical patients 
experience complications such as facial paralysis, neurologic damage, CSF fistula, hematoma, 
hydrocephalus, and even death61-63.   
 Radiosurgery is increasingly chosen over surgery as a noninvasive treatment option, 
but there are still a significant number of cases in which the treatment either fails to control 
the tumor growth or the tumor eventually recurs. Surgical resection is typically the next 
course of action in these cases because further radiation therapy would exceed normal tissue 
dose tolerances. In a study by Yomo et al on repeat radiosurgery for acoustic neuroma 
patients, two patients required as many as three Gamma Knife treatments (with prescription 
doses of 12, 12, and 14 Gy) before achieving tumor control89. None of the patients in this 
study maintained useful hearing after receiving repeat radiosurgery. Although an initial 
target dose of 12 Gy was clearly insufficient for achieving or maintaining tumor regression 
in these patients, the delivery of larger single-fraction doses is typically limited by normal 
tissue tolerances. 
 Using noncoplanar conformal and dynamic arcs on a modern linac, dose conformity 
nearly as good as that with Gamma Knife can be achieved, without the toxic high maximal 
doses82,83. As demonstrated in this study, 4π radiotherapy can enable statistically significant 
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reductions in both mean and maximum normal tissue doses, particularly to the cochlea and 
brainstem. As previously mentioned, clinical studies have found that patients who receive 
<4.2 Gy single fractional doses to the cochlea experience significantly better hearing 
preservation than patients who receive >4.2 Gy.  
 Our study shows that for patients treated with a single fractional SRS dose, the mean 
cochlear dose can be reduced from 6.29 Gy to 4.25 Gy, allowing potentially significant 
reductions in hearing loss. On the other hand, we showed that prescription doses for the 4π 
plans can be escalated to achieve 99.5% tumor control while maintaining hearing loss 
probabilities below the non-escalated clinical plans.  The ability to safely escalate 
prescription doses would likely reduce the incidence of tumor recurrence and the need for 
subsequent tumor resection or secondary radiation, both of which carry major risks of 
hearing loss or other complications. 
 In this study, heterogeneous planning techniques including conformal arc, IMRT, 
and VMAT were used clinically, mainly depending on the size of the tumor. Conformal arcs 
are typically used on smaller tumors, while larger tumors benefit from the better dose 
homogeneity and conformity that can be achieved with intensity modulation in static IMRT 
and VMAT. Nevertheless, 4π radiation therapy resulted in consistently improved cochlea 
sparing in individual planning technique comparisons.  
 The noncoplanar beams were not actually delivered in this study. However, in a 
separate prospective clinical study85, a similar number of beams were delivered to patients 
with brain tumors. In this study, the beams were ordered on the basis of their couch rotation 
angles. That way, the treatment could be delivered in a single couch sweep while the gantry 
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rotated back and forth under the guidance of pretreatment modeling40. With remote manual 
machine operation, the treatment delivery time was less than 35 minutes. In the phantom 
test using fully automated machine control that has not been approved for patients, the same 
treatment could be delivered in <15 minutes. We expect similar treatment times for patients 
with acoustic neuroma. 
2.2.5 Conclusions 
 4π radiotherapy achieves significantly greater normal tissue sparing compared with 
radiotherapy techniques that are typically used in acoustic neuroma treatment. These major 
reductions in cochlear dose may reduce the risk of normal tissue complications such as 
hearing loss and enable the safe escalation of prescription doses to potentially improve 
tumor control rates. 
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2.3 4π Plan Optimization for Cortical-Sparing Brain 
Radiotherapy28 
2.3.1 Introduction 
 Thinning of the cerebral cortex has been observed in patients treated with 
fractionated partial brain radiation therapy and may contribute to cognitive decline 
following treatment. The extent of this thinning is dose-dependent, as illustrated in Figure 
2-9, and has been shown comparable to that of neurodegenerative diseases such as 
Alzheimer’s disease at one year post-therapy90. 
 
Figure 2-9 A representation of the cortical surface from Karunamuni et al90 showing the dose 
delivered (A) and the extent of cortical thinning one year post-irradiation (B) for an example patient. 
 The objective of this study was to investigate whether 4π radiotherapy can enable 
better sparing of the cerebral cortex and other critical structures when compared to 
conventional clinical IMRT plans. This could potentially reduce the degree of cortical 
thinning, and subsequent neurocognitive decline, observed in high-grade glioma patients 
following radiation therapy. 
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2.3.2 Methods 
2.3.2.1 Patient population and treatment 
 This retrospective study was approved by the institutional review board. The 
patient cohort consisted of nine male and four female subjects (median age 60 years, range 
40-77) with high grade glioma. Patients were treated on a 6 MV TrueBeam (Varian Medical 
Systems, Palo Alto, CA) linear accelerator with a 120-leaf Millennium MLC to a prescription 
dose of 59.4 Gy (N=1) and 60 Gy (N=12) in 33 or 30 fractions, respectively. All patients’ 
original clinical plans were six to eight noncoplanar field, fixed-gantry, sliding-window IMRT. 
The original IMRT plans were obtained and re-planned with 4π radiation therapy 
optimization. 
2.3.2.2 Radiation planning objectives 
 The original fixed gantry IMRT plans were optimized to meet clinical objectives for 
PTV coverage and standard OARs (including brainstem, optic structures, and spinal cord) at 
the time of treatment. Dose constraints matched guidelines set by RTOG 082591, including 
maximum doses of <60 Gy to the brainstem, <55 Gy to the optic nerves, and <56 Gy to the 
optic chiasm. Beam arrangements for these plans were selected by the treating physician 
and dosimetry team to most effectively achieve the planning goals for each case. These 
original clinical plans were not optimized for cortical sparing. For each case, two new plans 
were created to spare the cortex: IMRT-optimized and 4π-optimized. Cortical sparing for the 
IMRT-optimized plans was performed to minimized cortical volume outside the PTV 
receiving doses higher than 30 Gy92, with the highest priority given to the cortex. In 4π 
planning the highest constraint for each case was also placed on the normal cortex, with the 
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other OARs prioritized based on proximity to the tumor. The overarching goal was to 
minimize OAR doses while matching the primary objective for PTV coverage in the original 
plan. The same objectives and priorities were used for the cortical-sparing IMRT plans and 
cortical-sparing 4π plans. Doses in all plans were normalized to deliver 100% of the 
prescription to 95% of the PTV volume.  
2.3.2.3 4π optimization 
 The 4π treatment planning process is a highly noncoplanar and non-isocentric 
system developed on C-arm gantry linear accelerators, and has been described in detail 
previously8-10,26,93. Briefly, the 4π planning process began with 1162 candidate beams evenly 
distributed throughout the solid sphere angle space, with 6° separation between beams. A 
CAD model of the Varian TrueBeam linear accelerator with a 3D-scanned human surface 
model positioned on the couch was utilized to exclude any beams causing a collision between 
the gantry and couch or patient40. Dose contribution matrices with 2.5 x 2.5 x 2.5 mm3 
resolution were computed for each of the candidate beams using convolution/superposition 
of a 6 MV polyenergetic x-ray kernel. A greedy column generation algorithm with defined 
upper dose constraints and structure priority weighting, was used to iteratively select 20 
beam orientations, such as those shown in Figure 2-10, and perform fluence map 
optimization. To compare with the clinical plans without any bias from different dose 
calculation methods, the optimal beam orientations were then imported into Eclipse for dose 
recalculation using an identical dose calculation engine and resolution. 
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2.3.2.4 Dosimetric comparison 
 The mean and maximum dose to the cerebral cortex and other OARs were compared 
for the two cortical-sparing plan types, as well as the conformity index (CI), homogeneity 
index (HI), and 50% dose spillage volume (R50) to assess the target coverage and dose 
spillage. CI was defined as the ratio of the volume receiving the prescribed dose to the 
volume of the PTV, and HI as the ratio of the 95% and 5% isodose volumes. R50 was defined 
as the ratio of the 50% isodose volume to the PTV volume. 
 
Figure 2-10 Orientation of the beams used in the clinical IMRT plan (left) and the 20 optimal beams 
selected by the 4π algorithm (right) for one patient in the study. 
2.3.3 Results 
 As shown in Table 2-9, the 4π plans significantly reduced the mean cortical dose by 
an average of 15% (ranging from 6% to 27%) compared to the clinical plans. The mean dose 
to every other OAR compared was also reduced by 15% to 42%, with statistically significant 
reductions to the brainstem, chiasm, right eye, optic nerves, subcortical white matter, and 
hippocampus. The average maximum doses were also reduced for 10 out of the 12 OARs 
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compared, with statistically significant reductions in the maximum dose to the brainstem, 
chiasm, hippocampus, and subcortical white matter. These significant reductions in OAR 
doses are evident in the dose volume histograms for one representative patient (Figure 
2-11) and averaged over all patients in the study (Figure 2-13). The R50 was significantly 
reduced with the 4π plans by over 14%. This significant reduction in high dose spillage is 
also evident in the dose washes shown in Figure 2-12, particularly in the axial view. 
Table 2-9 Dose statistics for clinical and 4π plans for the 15 high-grade glioma patients in this study 
Plan 
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Clinical 
Mean 19.7 18.6 20.1 23.1 16.3 15.5 
8.5 51.6 4.4 0.84 1.73 
Max 45.5 28.4 29.1 49.6 54.0 53.0 
4π 
Mean 12.9 12.8* 12.2* 14.6* 13.8* 13.1* 
8.0* 52.5 3.8* 0.86* 1.72 
Max 49.3 37.2* 20.5* 45.0* 52.7* 53.1 
*Significantly lower dose (or higher homogeneity) than the clinical plans (2-tailed t-test, p<0.05) 
 
 46 
 
Figure 2-11 Dose volume histograms of the 4π (dashed) and clinical (solid) plans for the patient in 
Figure 2-10. 
 
 
Figure 2-12 Dose washes of the 4π and clinical plans for the patient in Figure 2-10. Structures: 54 
Gy PTV (green), 60 Gy PTV (blue), and cerebral cortex (gray).  
 47 
 
Figure 2-13 Dose volume histograms of the cortex and PTV (60 Gy prescription level) for the 4π 
(dashed) and clinical (solid) plans averaged over all 15 patients. 
2.3.4 Discussion 
 Reducing the volume of incidentally irradiated normal brain structures in brain 
radiotherapy may help to lower the probability of cortical, white matter, and hippocampal 
damage that could lead to neurocognitive deficits. A previous study showed that cortical 
sparing was feasible by heavily prioritizing cortical dose in standard IMRT planning92. This 
study investigated whether the cortical dose could be further reduced using new planning 
methods without compromising other planning metrics such as PTV dose homogeneity. 
Cortex-sparing IMRT plans were compared to 4π-optimized IMRT plans, and 4π improved 
sparing of all standard OARs, including the brainstem and optic structures. 4π also 
significantly reduced the volume of the cortex receiving over 30 Gy, and since doses over 30 
Gy increase (by 20% or greater) the probability of severe cortical thinning92, 4π-optimized 
IMRT has the potential to lower cortical injury. 
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 In whole brain radiotherapy patients, dose to the hippocampus is hypothesized to 
cause post-treatment decline in verbal memory94, and a recent quantitative MRI study 
reported dose-dependent hippocampal atrophy after brain radiotherapy95. Notably, even 
though none of the plans were optimized with respect to the hippocampus, 4π significantly 
reduced the mean dose to the hippocampus by 37% compared to the cortical-sparing IMRT, 
suggesting that this technique would also be helpful for hippocampal sparing. Also, while 
cortical sparing in optimized IMRT was achieved at the price of increased inhomogeneity of 
PTV coverage, 4π optimization allowed for better cortical sparing without significant 
reductions in homogeneity. The reduced dose to the hippocampus and white matter with 4π 
appears to be an additional benefit of limiting dose spillage outside the PTV. 
2.3.5 Conclusions 
 4π radiation therapy, which utilizes optimized highly noncoplanar beam 
orientations, has been shown to enable significant sparing of the cerebral cortex, as well as 
other critical structures, when treating high-grade gliomas. Previous research suggests that 
this could reduce the risk of harmful dose-dependent cortical thinning, which may be the 
cause of neurocognitive decline observed in such patients following radiation therapy. 
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3 DOSIMETRIC EVALUATION 
TOOLS FOR PRECLINICAL 
RADIOTHERAPY 
3.1 Small Animal Irradiation Standardization Project 
3.1.1 Introduction 
  Despite significant advances in the field of radiation biology, many of the biological 
effects of radiation exposure have yet to be explained. The most widely used research tools 
for studying these mechanisms are small animal models, particularly the mouse model16,17. 
Over recent years, more advanced small animal irradiation systems have been developed 
that enable image guidance and feature dedicated treatment planning systems for more 
precise dose calculations96,97. These new capabilities could greatly expand the potential for 
preclinical studies, enabling much higher dosimetric and geometric precision98. However, 
because this technology is relatively new, there is a significant lack of standardization across 
different small animal radiotherapy platforms and different research institutions99. One of 
the goals of the Radiation Physics Core of the UCLA Center for Countermeasures against 
Radiation (CMCR)100 is to evaluate and mitigate these inconsistencies in small animal 
dosimetry. 
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3.1.2 Methods 
3.1.2.1 Phantom development 
 First, cylindrical phantoms were developed that are simple to manufacture but also 
incorporate some tissue heterogeneity for mimicking the mouse anatomy. These phantoms 
are similar in size to a typical mouse (3 cm diameter and 10 cm long) and are made of 
polystyrene that can be split at the center for the insertion of dosimeters and radiochromic 
film. Polystyrene has a density of 1.02 g/cm3, which is close to that of soft tissue.  These 
phantoms also have higher density “bone” inserts (Teflon rod, 2.2g/cm3) for the spine and 
legs and low density inserts (0.3 g/cm3  Polyurethane rod, McMaster-Carr) for the lungs (see 
Figure 3-1). The phantom has triplet TLD slots in five different locations in the head, chest, 
abdomen, and pelvis, and room for six additional TLDs in the lungs. Radiochromic film is cut 
with a digital film cutter (Silver Bullet) to fit between the two phantom halves. 
 
Figure 3-1 Photograph (left) and CT scan (right: coronal view of the lower (A) and upper (B) 
phantom halves; axial view through the lungs (C)) of the cylindrical polystyrene mouse phantoms, 
with higher density inserts in the spine and legs and lower density foam inserts in the lungs. It has 
groups of three TLD slots in the head, spine, left and right abdomen, and pelvis. Custom die-cut film 
is inserted between the two halves. 
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 A mouse phantom with a more anatomically accurate shape was also developed, 
which we refer to as “mousemorphic”. A CAD model was created based on micro CT of a 
C57B1/6 mouse and split along the midcoronal plane for dosimeter insertion. Three 
different versions of the phantom were created with slots for thermoluminescent dosimeters 
(TLDs), optically stimulated luminescent dosimeters (OSLDs) or Alanine dosimeters. The 
CAD models for all three phantom types are shown in Figure 3-2. These mousemorphic 
phantoms, shown in Figure 3-3, were first printed using fused deposition modelling (FDM) 
3D printing with acrylonitrile butadiene styrene (ABS) filament on the MakerGear M2 
printer. ABS is close to tissue-equivalent, with a density of 1.04 g/cm3. Initial dosimetric 
calibration was performed using a 225 kVp x-ray machine with Monte Carlo dose calculation. 
Using the SmART Advanced Treatment Planning (ATP) System (SmART Scientific Solutions, 
Maastricht, Netherlands) and assuming tissue equivalency of ABS in the Monte Carlo 
simulation (SmART Plan version 1.3, pegs 4 material Tissue), the measured dose was 1.2% 
off from the calculated dose, as shown in Figure 3-4, suggesting that ABS mousemorphic 
phantoms are good surrogates for dosimetric testing. Inter-phantom variation, assessed by 
weight, was less than 0.5%, suggesting consistent print density and dimensions. These ABS 
phantoms were used for all institutional dosimetry measurements in this study. 
 A second version of the mousemorphic phantom was printed on the Formlabs Form 
2 stereolithography (SLA) 3D printer with Flexible Resin, which enabled higher print 
resolution and success rates (Formlabs, Somerville, MA). This material is also very 
radiographically similar to tissue, with average Hounsfield Unit (HU) measurements 
differing by <2% compared to tissue measurements from real animal CT data. These 
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measurements are shown and further discussed in section 3.2, and the printed phantom is 
shown later in Figure 5-9. 
 
Figure 3-2  CAD models of the full mousemorphic phantom with dimensions (upper left) and the 
design variations for TLD, OSLD, and Alanine dosimetry. 
 
 
Figure 3-3 Phantoms 3D printed out of ABS from the CAD model shown in Figure 3-2. The weight of 
the phantom is 24.5 ± 0.1 g. 
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Figure 3-4 Monte Carlo dose calculation in the SmART-ATP system assuming tissue equivalence 
(left) and measured phantom film dose (right). 
3.1.2.2 Dosimeter calibrations 
 Calibration curves were then developed for TLD, OSLD, and EBT3 film dosimetry for 
the standardization surveys described in the following section. A wide range of photon 
energies are used for small animal irradiation, which is one of the challenges with 
standardization. This variation was reflected in these surveys, which included systems using 
225 to 320 kV x-ray tubes, 6 MV linear accelerators, and Cs-137 sources. In order to 
accurately compare the measurements between these systems, energy correction factors 
were also derived for each type of dosimeter. 
TLDs 
 TLDs were first annealed using the procedure recommended by Yu et al101 (400°C 
for 1 hour, followed by 105°C for 2 hours). These annealed TLDs were irradiated at 
calibration doses of 0, 1, 4, 8, and 16 Gy, and a pre-readout anneal was performed (105°C for 
15 minutes, then cooled for 5 minutes). The TLDs were then read out and a quadratic 
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calibration curve was created with the measurements. Energy correction factors were 
calculated using literature data102 and a decay factor of 3x10-4 Gy/day was used to correct 
for time between irradiation and readout. 
OSLDs 
 The Landauer microSTARii Medical Dosimetry System was used for the calibration 
of the nanoDot OSLDs. Screened nanoDots, which had been individually tested to ensure high 
accuracy in sensitivity determination (±5.5%) were used for all calibration and 
measurements. A high dose nonlinear calibration was created for a 225 kVp x-ray beam 
using the SmART. Three screened nanoDots were irradiated at 225 kV to each dose level: 0.5, 
1, 3, 5, 8, 10, and 13 Gy. The irradiation was performed using 305.4 mm SSD, 4 x 4 cm 
collimator, large focal spot, and 0.32 mm Cu filtration. Each nanoDot was then measured four 
times using the microSTARii system, and a standard deviation of <0.05 across all sensitivity-
corrected counts for each dose level was verified before accepting the calibration. This 
calibration was used for reading out OSLDs irradiated with 225 to 320 kV photons.  
Correction factors for energies >225 kV, given in Table 3-1, were determined from data 
provided by Landauer. 
 Landauer also supplied calibration sets for 80 kVp and Cs-137, with nanoDots 
irradiated to 0.5, 3, 50, and 100 rad (with three nanoDots at each dose level). Low dose linear 
calibrations were created for each energy using the process above. This higher energy 
calibration was used for OSLDs irradiated with Cs-137 or 6 MV photons. 
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Film 
 Gafchromic EBT3 film (Ashland Inc., Covington, KY) was irradiated on the SmART 
system at 225 kV to doses of 0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 Gy (although fewer 
calibration points could have been used). The film was scanned on an Epson 10000XL 
scanner with a resolution of 96 dpi in 48-bit RGB (red, green, and blue), and Ashland’s 
FilmQA Pro software was used to create the calibration curve and to perform all subsequent 
film measurements. EBT3 film energy response data from the literature103 was used to 
calculate the correction factors given in Table 3-1. Film measurements were also corrected 
for the time between irradiation and measurement (which was significant in some cases due 
to shipping times) assuming an optical density increase of 5x10-4/day (if kept in the dark, as 
instructed).  
Table 3-1 Energy correction factors for TLD, OSLD, and EBT3 film measurements 
Irradiation 
Energy 
TLD 
OSLD 
EBT3 Film 
225 kV readout Cs-137 readout 
225 kV 1 1 - 1 
250 kV 1.067 1.070 - 0.991 
320 kV 1.098 1.204 - 0.970 
Cs-137 1.086 - 1 0.909 
6 MV 1.114 - 1 0.909 
 
3.1.2.3 Measurement procedure 
 Each cylindrical and mousemorphic phantom was loaded with custom die-cut pieces 
of EBT3 film and TLDs or OSLDs. Each phantom pair was then sent out for remote dosimetry 
to institutions across the country with specific instructions for phantom irradiation to 4 Gy. 
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After irradiation, the phantoms were shipped back to UCLA along with relevant experimental 
details such as irradiation energy, system, exposure time, and filtration. The TLDs, OSLDs, 
and film were measured and corrected for irradiation energy based on the factors given in 
Table 3-1, as well as the time since irradiation. The survey was then repeated to assess the 
reproducibility of the dosimetric measurement based on the dose to the cylindrical phantom 
shown in Figure 3-1. This comparison was based on the average film dose measurements 
from four tissue-like regions of the phantom, as indicated by the red regions-of-interest 
(ROIs) on the sample film in Figure 3-5. For the third survey, the necessary change in 
exposure time was calculated based on the deviation between measured and expected dose 
and communicated to the participating institutions. 
 
Figure 3-5 Film measurement from one of the cylindrical mouse phantoms. Average dose was 
measured within the four regions indicated by red squares. 
3.1.3 Results and Discussion 
Dose deviations of up to 30% were measured in the first two surveys. After modifying 
exposure times accordingly, all but one center was able to improve the dosimetric deviation 
from the expected value to within 7%, as shown in Figure 3-6. However, this center later 
realized that the exposure time was not adjusted according to the revised instructions. They 
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are now aware of this consistent deviation and will adjust future exposure times accordingly. 
For irradiator #6, the large dose heterogeneity in the second survey resulted from improper 
animal setup, which was consistently used at the institution prior to this survey. When this 
setup error was corrected in the harmonization survey, the heterogeneity was reduced to 
2% and the absolute dose error reduced to 1%. 
 
Figure 3-6 Dosimetric harmonization test results. Measured dose is given as the average dose from 
the four regions-of-interest of the cylindrical phantom film (as shown in Figure 3-5) with error bars 
indicating the standard deviation. Irradiators #6 and #8 did not participate in the first survey, and 
the harmonization result of #3 was not valid. The exposure parameter for #5 was not adjusted. 
 
Although these results are fairly consistent, it should be noted that deviations 
between the film and TLD measurements of up to 20% were observed for a few of the 
phantoms. This is likely due to uncertainties in energy correction, since these deviations 
were significantly smaller for exposures at 225 kV (when no corrections were needed). Even 
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with accurate energy response relationships, there may still be significant uncertainties in 
this correction due to the unknown energy spectrum of each irradiation system.  
 To address this uncertainty, a phantom was developed for beam characterization 
(Figure 3-7). This phantom features five separate regions for TLD and film measurement, 
with different thicknesses of copper above each region: 0, 1, 2, 3, or 4 mm. The phantom is 
3D printed with water-equivalent plastic resin, and there is an equal thickness of plastic 
above each region. This simple, compact measurement tool (approximately 5 x 5 x 2.5 cm) is 
designed to be shipped with the mouse phantoms and irradiated under identical conditions. 
By measuring the dose below each filtration level, we can calculate the relative copper half-
value layer (HVL) of the beam and perform a more accurate energy correction (Figure 3-8). 
 
 
Figure 3-7 CAD model of the portable phantom developed for beam energy spectrum 
characterization. Each region of the phantom has the same thickness of plastic (left), above four 
different thickness of copper (center). Below the copper there are inserts for three TLDs in each 
region, including the 0 mm region (right). Film is inserted above the TLDs, with a shim in between to 
prevent scatter. 
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Figure 3-8 (Left) The measured film distribution for one of the half-value layer (HVL) experiments, 
with labels for the copper thickness above each region. (Right) Measured film doses (normalized to 
1) and best-fit exponential curves for the HVL phantom irradiated with 300 kV x-rays, 225 kV x-rays 
with an aluminum filter, and 225 kV x-rays with a copper filter. A simple exponential relationship 
cannot accurately model the attenuation of polyenergetic beams, which is most evident for the 225 
kV beam with aluminum filtration. 
3.1.4 Conclusions 
 Several useful tools were developed for small animal dosimetry, including an 
anatomically accurate mouse phantom and a portable beam energy characterization 
phantom. These can be used to assess the significant inconsistencies in preclinical irradiation 
techniques between different institutions. The results of the dosimetric harmonization 
survey strongly suggest the need for increased collaboration between physicists and 
biologists on the design and execution of preclinical studies. Low cost, straightforward 
standard quality assurance protocols are needed for these systems to minimize dosimetric 
inaccuracies and help achieve more consistent small animal irradiation research results. 
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3.2 A 3D Printed, CT-Generated Monkey Phantom with 
Tissue and Bone Equivalent Materials 
3.2.1 Introduction 
 Anthropomorphic phantoms mimicking realistic tissue radiographical properties 
are important in therapy and imaging practices. However, conventional anthropomorphic 
phantoms are expensive, limited in option, and lack flexibility. 3D printing is a viable 
technology for fabricating custom phantoms, but a process to print and assemble 
anatomically and radiographically realistic phantoms has not yet been demonstrated. In this 
study for non-human-primates, we developed and characterized a phantom from CT images 
using 3D printed materials that closely mimic the x-ray attenuation properties of soft tissues 
and bone. This straightforward and inexpensive technique could greatly increase the 
feasibility and value of phantom studies for a wide range of applications, such as material 
decomposition or proton stopping power measurements. 
3.2.2 Methods 
 CT images were acquired for a 3 kg male rhesus monkey and segmented by 
Hounsfield Units (HU) into bone, lung, and soft tissues using MATLAB (The Mathworks Inc., 
Natick, MA). The model was then imported into Autodesk Inventor 3D CAD software for 
further manipulation (Autodesk, San Rafael, CA). A honeycomb structure was added within 
the lung volume to create the structure density necessary to mimic realistic lung CT values. 
This structure consisted of two overlapping hexagonal honeycombs, with side length of 4 
mm and wall thickness of 0.42 mm, offset laterally by one side length. Removable 
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thermoluminescent dosimeter (TLD) holders were created in the chest and abdomen of the 
model, and a midsagittal split was made for film dosimetry. The phantom was then further 
segmented for printing and assembly.  
 All phantom segments were then printed using the Formlabs Form 2 3D printer. The 
Formlabs Flexible Resin was used to print all soft tissue and lung segments, and the Ceramic 
Resin was used to print the bone segments. Although the Ceramic Resin is intended to be 
fired after printing, we found that the unfired state was better suited for this application. 
Although the parts are quite brittle after printing, this was not a major concern because the 
“bones” are fully encased within the flexible “soft tissue”. Also, the unfinished state actually 
improved the phantom assembly process by allowing the parts be sanded down where 
necessary for better mating. The phantom was designed to split into three segments – 
head/arms/chest, abdomen, and pelvis/legs – and all other permanent connections were 
made using superglue.  
 After assembly, the material properties of the phantom were assessed. CT scans 
were acquired of the phantom pelvis, spine, and lungs using the cone-beam CT imaging 
capabilities of the X-RAD SmART system. HU measurements were compared between the 
original monkey CT and the phantom CT for regions of interest in soft tissue, lung, and bone. 
A treatment plan was also created on the SmART-ATP system to deliver a dose of 8 Gy to a 
10 mm target in the phantom chest in one full arc, using real tissue, lung, and bone material 
properties for Monte Carlo dose calculation (SmART Plan version 1.3, pegs 4 materials 
Tissue, Lung, Bone). 
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3.2.3 Results 
 The phantom segments were printed and assembled, with examples of both material 
types shown in Figure 3-9. The phantom CT scan showed good agreement with the original 
monkey CT in terms of average HU, as illustrated in the example ROIs in Figure 3-10. The HU 
values were compared for bone, tissue, and lung using the average measurements from six 
ROIs for each material throughout the whole phantom (1 cm diameter ROIs for tissue and 
lung, 5 mm diameter for bone). The average CT measurements for soft tissue differed by 53.5 
HU between the real monkey and the phantom (52.5 HU and -1.0 HU, respectively), which 
corresponds to a difference of only 2.7% on the HU scale. The average lung measurements 
differed by only 1.8%, with -745.7 HU for the real monkey CT and -780.9 HU for the phantom 
CT. The bone had the closest average measurements, with a difference of only 1.3% (1082.3 
HU for monkey, 1055.4 HU for phantom). 
 
Figure 3-9 3D printed monkey phantom parts. The bone segments were printed out of Ceramic Resin 
(left) and soft tissue out of Flexible Resin (center). Inserts in the phantom abdomen and chest were 
designed for TLD dosimetry (right). 
 
 The calculated and measured dose distributions for this plan are shown in Figure 
3-11. The measured film dose from the test treatment plan also showed good agreement with 
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the calculated dose distribution, with <1 Gy difference between the delivered and calculated 
mean target dose. This suggests that the phantom materials may serve as good surrogates 
for real soft tissue, lung, and bone for dosimetric testing. 
 
Figure 3-10 CT images for the real monkey (left) and phantom (right) in the pelvis (upper) and spine 
(lower). The center slit in the phantom pelvis was designed for film insertion. Measured HU values 
for ROIs in the soft tissue and bone (shown in green) are given on the right. (HU: Hounsfield Units) 
 
Figure 3-11 (Left) Calculated dose for the phantom test plan, with a prescription dose of 8 Gy to a 10 
mm target in the phantom chest delivered in one full arc. Real tissue, lung, and bone material 
properties were used for dose calculation. (Right) Measured dose from film inserted into the 
midsagittal slit in the phantom chest, at the same plane as the calculated dose shown in the center. 
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3.2.4 Discussion 
 There were some challenges in the development of this phantom that will be 
improved upon in the next version. The brittleness of the unfired ceramic material was an 
issue for very small phantom parts, such as the ribs and vertebrae. Several of these bones 
broke during assembly, which was evident from the phantom CT images. This could be 
alleviated by slightly simplifying the bone structure, as long as this does not significantly 
affect the phantom dosimetry. This was also a very small monkey – only 3 kg – and would 
likely not be an issue with a larger primate or human phantom. The recent development of a 
larger version of the 3D printer used in this study would also enable the use of this technique 
(with the same resins) for larger phantoms. 
 Although further testing is necessary, preliminary measurements of the phantom 
show good agreement with the radiographical properties of real tissue and bone. More 
rigorous measurements of absolute dose will be performed using the abdominal and chest 
inserts shown for TLD dosimetry in order to more accurately assess the electron density of 
the phantom materials. A full-body scan will also be acquired with the phantom fully 
assembled. This will help to assess the overall fit of the bone structure within the soft tissue 
and identify any areas for improvement. 
3.2.5 Conclusions 
 A CT-specific 3D printed monkey phantom was developed that closely mimics the 
CT values for soft tissue, lung, and bone, providing a useful preclinical research tool and 
establishing a method for creating more anatomically accurate custom phantoms. This 
straightforward and inexpensive technique could greatly increase the feasibility and value 
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of phantom studies for a wide range of applications, such as material decomposition or 
proton stopping power measurements. 
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4 SOC PLANNING SYSTEM 
DEVELOPMENT AND 
COMMISSIONING 
4.1 Introduction 
 Since over 50% of cancer patients can benefit from radiation therapy2,18,104, it is not 
surprising that this is a field of extensive research and constant technological advancement. 
As a result, improvements in radiotherapy techniques have greatly increased dose 
conformity and normal tissue sparing. Intensity modulated radiation therapy (IMRT), the 
current clinical gold standard, allows for the delivery of extremely precise, complex dose 
distributions, enabling the use of escalated doses and more novel techniques such as dose 
painting. However, the clinical benefits from improved dose distributions alone will likely 
plateau due to normal tissue tolerances and may not improve outcomes for radioresistant 
tumors105. This highly conformal treatment is possible due to advancements in image 
guidance and treatment planning technology, both in terms of hardware and software, but 
this has been driven by physics and engineering developments rather than emergent 
knowledge of the underlying radiobiology of tumors and normal tissue. In order to better 
understand which novel treatment techniques will actually translate to improved clinical 
outcomes, preclinical validation is required.  
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Small animal models, particularly mouse models, are the most widely used tool for 
preclinical research, providing a low-cost, versatile way to gain valuable insight into cancer 
growth and radiation effects16,17. They also provide a practical avenue for testing the safety 
of new drugs and combination therapies prior to human exposure. However, the translation 
of these results to clinical outcomes is extremely poor18-21. A systematic review by Hackman 
et al106 showed that out of 76 highly-cited animal studies only 28 were replicated in human 
trials, and 14 of these had outcomes contradicting the animal trials. There was even a NCI 
Radiation Research Program workshop held to discuss the “Lessons Learned from Radiation 
Oncology Clinical Trials” in which ten well-designed, randomized clinical trials from the 
Radiation Therapy Oncology Group were examined, with nine of these resulting in null or 
negative results107.  
For these preclinical radiotherapy studies, translation is limited in large part by the 
irradiation techniques used99. Differences in fractionation and treatment setup can 
drastically change the response of cancer cells to radiation108,109. The use of much lower 
energy x-rays for small animals (kilovoltage vs. megavoltage) results in different dose 
distributions within the tissue, as well as potential differences in relative biological 
effectiveness110-112.  The use of very small field sizes can also be an issue, since both the dose 
rate and the dose prediction accuracy decrease significantly96. Previously, preclinical studies 
used only crude irradiation techniques and protocols that did not account for these factors. 
These studies typically used radiation systems intended for human use, which are not nearly 
precise enough for the small animal scale. Very limited imaging was used, partially due to 
the inability of these human systems to achieve the resolution required for small animals. 
This lack of geometrical targeting necessitated the use of large radiation fields, therefore 
 68 
delivering high doses to normal tissue as well. Most preclinical research thus far has been 
done with these single large fields and very crude dose calculations, in stark contrast to the 
highly conformal, precisely calculated (and verified) doses delivered clinically99.  
The recent development of image-guided small animal irradiators has therefore 
greatly expanded the potential for preclinical radiotherapy studies98. The two main systems 
are the Small Animal Radiation Research Platform (SARRP) (Xstrahl Inc., Suwanee, GA) and 
the X-RAD SmART (Precision X-Ray, Inc., North Branford, CT). These systems both feature 
cone beam CT imaging and their own dedicated treatment planning systems (Muriplan and 
SmART-Plan, respectively). For both irradiators, beam collimation is typically achieved using 
interchangeable circular or rectangular inserts ranging from 1 mm diameter to 10 x 10 cm 
square97,113.  
In order for preclinical studies to accurately predict patient outcomes, the techniques 
employed must be analogous to those used in the clinic. IMRT relies on inverse fluence map 
optimization combined with dose modulating hardware, both of which must be adapted for 
the small animal scale in order to successfully employ this technique in preclinical studies. 
While the two systems mentioned above offer major improvements in preclinical 
radiotherapy techniques, they still lack the necessary foundations for IMRT. Clinical dose 
modulation is achieved with a dynamic multileaf collimator (MLC), but due to its complexity, 
the miniaturization of the dynamic MLC for small animals is extremely difficult and has yet 
to be achieved. While small animal IMRT has been attempted without an MLC by raster 
scanning with a 1 mm cone, this technique is prohibitively slow and is subject to significant 
uncertainties due to improper beam modeling for small field sizes25. While there have been 
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several other attempts to develop a miniature dose modulation device, none have proven 
feasible for small animal IMRT. These previous efforts are described in Chapter 5, which 
focuses on the hardware development and commissioning.  
In this study, we introduce a new method to deliver small animal IMRT using the 
previously described sparse orthogonal collimator (SOC)114, with four orthogonal leaf pairs, 
that can be more easily miniaturized for the small animal scale, and a planning system that 
supports the use of this simple dose modulation device. We demonstrate the performance of 
this new method on hallmark IMRT cases, including highly concave dose distributions and 
simultaneous integrated boost plans. We also detail the measurement and incorporation of 
beam commissioning data into our treatment planning system and the design for the SOC 
hardware. 
4.2 Methods 
This novel small animal IMRT method is based on the idea that direct aperture 
optimization (DAO) can be performed using only rectangular apertures for IMRT planning. 
We will first introduce the optimization algorithm, then describe the beam commissioning 
procedure and SOC design. 
4.2.1 Rectangular Aperture Optimization 
For SOC-based IMRT we have formulated the Rectangular Aperture Optimization 
(RAO), which has been described in more detail previously114, as 
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𝒂𝒓𝒈𝒎𝒊𝒏
𝜶
          
𝟏
𝟐
‖𝑾(𝑨𝑹𝜶 − 𝒅𝟎)‖𝟐
𝟐 + 𝝀‖𝜶‖𝟏           
𝒔𝒖𝒃𝒋𝒆𝒄𝒕 𝒕𝒐                           𝜶 ≥ 𝟎.                                  
Equation 4-1 
The optimization variable, 𝛼, is a vector of coefficients. The matrix 𝑅 is a scaling function 
which converts the coefficients from alpha to rectangular apertures in the fluence domain. 
Each column of 𝑅  represents one rectangular aperture in the fluence domain, which 
configures a direct correspondence between each coefficient in alpha and a rectangular 
fluence of varied size and position. The matrix A converts the fluence to the dose domain. 
The desired dose, 𝑑0 , is set to the prescription dose at the PTV and zero elsewhere. The 
diagonal weighting matrix W controls the relative importance of the structures of interest. 
The definition of the norm with parameter 𝑝, for some vector 𝑥 of dimension 𝑛, is ‖𝑥‖𝑝 =
√∑ |𝑥𝑖|𝑝
𝑛
𝑖=1
𝑝
 . The L2-norm fidelity term is used to penalize deviations from 𝑑0, and the L1-
norm encourages the vector 𝛼 to be sparse.  The regularization weighting term, 𝜆, is utilized 
to regulate the number of non-zero coefficients, and can be adjusted to meet the needs of a 
particular plan (i.e. to prioritize dosimetric quality or delivery efficiency). This problem 
formulation can be solved with a first-order primal-dual algorithm known as the Chambolle-
Pock algorithm115-118.  
The mapping, 𝑅,  represents discrete rectangles in the fluence domain, and the 
enumeration of every rectangle quickly becomes numerically intractable for fluence maps 
with a large number of beamlets. Instead, we start with an over-represented set of rectangles 
that have side lengths of 2𝑛 × 2𝑚, where 𝑛, 𝑚 ∈ {0,1,2, … , 𝑘}. The size of the fluence map is 
constrained to 2𝑘 × 2𝑘 . Since 𝑅 has a limited number of rectangles it represents, a step is 
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added to update 𝑅 with potentially important rectangles for selection. This step is performed 
in an alternating fashion with the optimization in Equation 4-1. The update method first 
takes pairwise combinations of all the apertures that have an associated non-zero coefficient 
from 𝛼. A new aperture is generated from the union of the aperture shapes from each pair, 
and is added to 𝑅 if the new aperture is rectangular and is unique to the current apertures 
available in 𝑅. The optimization in Equation 4-1 and this update method are alternated until 
no more new apertures are added to 𝑅. A detailed explanation of the initial over-represented 
set and the update method was previously described114. 
4.2.2 RAO Evaluation 
Three planning experiments were executed to validate RAO for SOC-based small 
animal IMRT. The aim of the first experiment was to evaluate the ability to create highly 
concave distributions and compare the quality of plans delivered with the SOC versus a 
hypothetical miniature MLC. A U-shaped target was first created on microCT images of a 
mouse brain (Mouse U). Two plans were created, one with a hypothetical conventional MLC 
having 0.5 mm resolution and the other with the SOC. The MLC plan was created by first 
performing a beamlet-based fluence map optimization, regularized by anisotropic total 
variation, as described in a previous publication119. The resulting fluence maps were then 
segmented such that the number of deliverable apertures matched that of the SOC plan. The 
U-shaped target was treated to 10 Gy. A SOC plan was then created for a more complex target 
volume with two overlapping U and C-shaped targets (Mouse UC). For the Mouse UC case, 
the non-overlapping volume was treated to 10 Gy, and the overlapping volume was treated 
to 12.5 Gy, a 25% dose boost. 
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In the second experiment, a 3D printed mouse phantom modeled from mouse CT data 
was used to demonstrate a realistic application for the SOC. One preclinical research area in 
which the SOC could be beneficial is investigating the role of radiation-induced damage-
associated molecular patterns (DAMPs) in cancer120 and ways to manipulate these immune 
responses in specific organs such as the liver121. In order to properly characterize these 
responses, it is necessary to deliver a conformal radiation dose to the liver while sparing the 
surrounding normal tissue and other organs. To simulate such an experiment, a mouse CT 
scan was acquired using contrast for better delineation of the liver and kidneys. Contours 
were drawn for these two structures and transferred to analogous positions on the body 
contour of the mouse phantom CT. The planning objective was to deliver a dose of 10 Gy to 
the whole liver while sparing the dose to the kidneys and surrounding normal tissue. 
The third experiment was designed to evaluate the level of 2D dose complexity 
achievable with the SOC and create a plan well-suited for evaluating the commissioning steps 
described in the following section. For this plan, an image of Audrey Hepburn was 
downsampled and simplified to three dose prescription levels of 2, 4, and 6 Gy. This target 
dose pattern lends itself to a wide range of aperture sizes, making it ideal for evaluating field 
size-specific effects on the dose distribution.   
For each of the mouse plans, the dose was calculated for 180 coplanar beams with 2° 
separation using a convolution/superposition algorithm with a 225 kV polyenergetic kernel 
tuned to match the PDD of the SmART system for a 2.5 cm (Mouse U and UC) or 1 mm (Mouse 
Liver and Audrey) field size. The justification and measurement of this 1 mm field size energy 
spectrum is detailed in a later section. The voxel resolution was 0.5 mm3 for the Mouse U and 
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UC plans and 0.1 mm3 for the Mouse Liver and Audrey plans. The 4π beam orientation 
optimization method, which has been previously published extensively9,10,12-15,26-28,85,122, was 
then used to find optimal beam angles for each plan. This optimization is based on a greedy 
column generation approach which iteratively selects beams from a candidate pool.  Since 
the Mouse U and UC plans aimed to evaluate the highest achievable SOC plan quality, 20 
optimal beams were selected and a beamlet size (and minimum aperture size) of 0.5 mm2 
was used.  The Mouse Liver case was planned more conservatively, with a more realistically 
deliverable beam count of 5 and a minimum aperture size of 1 mm2. The Audrey plan was 
also optimized for a 1 mm2 beamlet size. RAO was then applied for each plan, with a shell 
structure added around the PTV for the mouse plans to minimize dose spillage. The mouse 
plan doses were scaled to deliver the prescription dose to 95% of the target volume. 
As dosimetric endpoints for evaluation, R50 and PTV homogeneity (
𝐷95
𝐷5
)  were 
assessed. R50 is a measure of high dose spillage, defined as the ratio between the 50% isodose 
volume and the PTV volume. The van’t Riet conformation number (CN) was also assessed123. 
CN is defined as 𝐶𝑁 =
𝑇𝑉𝑅𝐼
𝑇𝑉
×
𝑇𝑉𝑅𝐼
𝑉𝑅𝐼
, where 𝑇𝑉𝑅𝐼  is the target volume covered by the 
prescription dose, 𝑇𝑉 is the target volume, and 𝑉𝑅𝐼 is the prescription dose volume. 
4.2.3 Beam Commissioning Measurements 
The optimization method described above assumes the same output, energy 
spectrum, and penumbra for all aperture sizes and locations, and does not account for any 
system-specific characteristics or imperfections. Therefore, a series of beam commissioning 
measurements, detailed in Table 4-1, were performed on our X-RAD SmART system in order 
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to improve the dosimetric accuracy of RAO IMRT plans delivered on this system. All 
measurements were done at an energy of 225 kV and source surface distance (SSD) of 30.5 
cm with 0.32 mm added copper filtration.  Film measurements were performed with 
Gafchromic EBT3 film (lot #10161801) (Ashland Inc., Covington, KY) and scanned on an 
Epson 10000XL scanner with a resolution of 96 dpi in 48-bit RGB (red, green, and blue). Film 
doses were analyzed with Ashland’s FilmQA Pro software using a red channel calibration 
curve created from the same film lot according to the manufacturer-recommended 
protocol124. The 40 x 40 mm square stationary collimator for the SmART system was used 
for the larger field measurements. All field sizes <40 mm were created using a prototype SOC 
system. Briefly, the SOC design consists of four pairs of orthogonal, double-focused tungsten 
leaves driven by Arduino-controlled stepper motors with rotary encoders for leaf position 
verification. The SOC system is mounted onto the 40 x 40 mm collimator of the SmART.  The 
complete design, fabrication, installation, and commissioning of the SOC is detailed in 
Chapter 5.  
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Table 4-1 SmART system beam commissioning measurement parameters 
Measurement Equipment 
Square field sizes 
(mm) 
Depth Calculation details 
Absolute 
output 
Ionization 
chamber, 
electrometer 
40 In air 
AAPM Task Group 61 
protocol125 
(average of 3 
measurements) 
Output factor 
EBT3 film, 
solid water 
sheets 
26, 20, 15, 10, 
5, 2.5, 1 
2 mm 
𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒(𝑓𝑖𝑒𝑙𝑑 𝑠𝑖𝑧𝑒 𝑥)
𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒 (26 𝑚𝑚 𝑓𝑖𝑒𝑙𝑑)
 
(average of 4 
measurements) 
Off-axis factors 
5, 2.5, 1 
(1.5 mm apart over 
entire SOC field) 
2 mm 
𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒( 𝑙𝑜𝑐𝑎𝑡𝑖𝑜𝑛 𝑥)
𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒 (𝑐𝑒𝑛𝑡𝑒𝑟)
 
Percent depth 
dose 
40, 20, 10, 5, 1 
20 depths, 
0-10 cm 
𝑚𝑒𝑎𝑛 𝑑𝑜𝑠𝑒( 𝑑𝑒𝑝𝑡ℎ 𝑥)
𝑚𝑎𝑥 (𝑎𝑙𝑙 𝑚𝑒𝑎𝑛 𝑑𝑒𝑝𝑡ℎ 𝑑𝑜𝑠𝑒𝑠)
 
Flatness 40 
2mm 
2cm 
4cm 
Percent variation from 
mean dose across central 
80% of FWHM 
(average of 5 line profiles) 
 
The measured off-axis factors were used to create off-axis “maps” for field sizes of 5, 
2.5, and 1 mm. These maps were then interpolated to estimate the output at any point within 
the full SOC field. Simplified maps were also created to compare the off-axis factors for 
different field sizes by averaging the measurements within nine equal regions of the SOC 
field. Preliminary measurements showed no significant difference in off-axis output for fields 
>5 mm. 
The measured PDD data was used to generate an estimated energy spectrum for each 
field size, with mean and maximum allowed PDD deviations of <2% and <5%, respectively. 
These spectra were obtained by first using the dose calculation method previously described 
with a virtual water phantom to generate 40 different PDD curves (spanning the range of the 
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measured curves) for beams with slightly different attenuation properties. The convex 
optimization software CVX (CVX Research, Inc., Austin, TX) was then used to find the optimal 
weighting of each curve to best match the measured PDD.  
Any average field flatness variations of ≤5% from the mean dose were not 
incorporated into the treatment planning system at this stage of commissioning. However, 
these measurements are necessary for assessing the overall system error. 
4.2.4 Plan Post-Processing 
This data was then integrated into the treatment planning process. Originally, the 
dose was calculated using a single general energy spectrum, previously tuned for a 20 x 20 
mm field on the SmART, and the plan was optimized using this dose matrix. However, this 
optimized plan may include a wide range of aperture sizes, and the calculated dose will 
theoretically only be accurate for 20 x 20 mm apertures. 
 Therefore, instead of performing the initial dose calculation with a single energy 
spectrum, this step was updated to calculate five different dose matrices using the estimated 
energy spectra for 1, 3, 5, 10, and 20 mm square field sizes. After optimization, the final 
apertures can then be separated by closest equivalent square field size, multiplied by the 
appropriate dose matrix and optimized weighting value (𝛼), and summed together to get a 
potentially more accurate, aperture size specific dose distribution. Since the plan quality is 
typically degraded to some extent after dose recalculation, the aperture weightings are then 
re-optimized to match the original optimized dose as closely as possible.  
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Since five different initial dose matrices are calculated now, the remaining question 
is which should be used for the initial optimization. This was explored by performing the 
rectangular aperture optimization for the same plan using the dose matrices for each of the 
five energy spectra. The difference between each optimized dose and the recalculated field 
size specific dose was then analyzed. The Audrey plan was ideal for this analysis because of 
its wide range of aperture sizes (a preliminary optimization selected apertures ranging from 
1 to 20 mm equivalent squares). 
The weighting for each aperture is then converted to a dwell time based on the 
measured absolute output and scaled by output factor using the equivalent square field size. 
In addition to output factor scaling, apertures ≤5 mm are matched by equivalent square size 
to the closest off-axis factor map and scaled according to their location within the SOC field.  
Once the final apertures and dwell times have been calculated, the plan is prepared 
for delivery with the SOC hardware, described in the following section. The basic SOC design 
enables apertures in diagonal quadrants to be delivered simultaneously, greatly improving 
the plan delivery efficiency. Therefore the apertures are then categorized by quadrant, and 
apertures in diagonal quadrants are combined to be delivered in parallel. The apertures are 
also sorted by dwell time prior to combination so that the longest times are paired together, 
further increasing delivery efficiency. 
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4.3 Results 
4.3.1 RAO Plan Analysis 
In the first experiment, the average number of deliverable apertures per beam was 
11.5 and 10.5 for the Mouse U and UC cases, respectively. Figure 4-1 shows the resulting dose 
distributions for highly concave RAO IMRT plans inside the mouse brain. Both hypothetical 
MLC and SOC plans achieved conformal dose distributions, but the SOC plans had higher 
homogeneity within the target volume. The poorer performance of the MLC is due in part to 
the extra segmentation step from the fluence map to deliverable apertures, which is avoided 
with the DAO method used for the SOC plans. The SOC was also able to create the more 
complex UC target while sparing the normal brain. The PTV homogeneity, R50, and CN for the 
Mouse U and UC cases are given in Table 4-2. For the Mouse U case, the SOC plans were 
superior to the MLC plans in all categories. The Mouse UC SOC plan achieved acceptable 
conformity and homogeneity while minimizing the high dose spillage. 
In the second experiment, RAO achieved a highly conformal dose to the mouse liver 
while sparing the dose to the kidneys, as shown in the DVH and dose wash in Figure 4-2, 
demonstrating a realistic application for the SOC. The plan achieved relatively high target 
homogeneity and conformity with low dose spillage, as demonstrated by the evaluation 
metrics given in Table 4-2. Most importantly, this high quality dose distribution was 
achieved using realistic delivery parameters of five beams and 1 x 1 mm minimum aperture 
size. 
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Figure 4-1 (Upper) Calculated concave dose distribution (with colorbar units in Gy) in the mouse 
brain delivered with a hypothetical MLC (A) and the SOC (B). Simultaneous integrated boost SOC plan 
(C) with a 125% dose boost to the overlapping target region. (Lower) Dose volume histogram 
comparisons for plans in (A-C). The SOC plans show a more homogeneous dose with less high dose 
spillage using the same number of segments. 
 
Table 4-2 Dose evaluation metrics for the mouse test cases (R50: 50% dose spillage; CN: 
Conformation Number) 
Plan Target Homogeneity R50 CN 
Mouse U (SOC) U 0.922 4.459 0.753 
Mouse U (MLC) U 0.815 4.818 0.626 
Mouse UC (SOC) 
U - C 0.888 
3.862 0.713 
C - U 0.896 
U ∩ C 0.914 N/Aa 0.711 
Mouse Liver (SOC) Liver 0.895 2.204 0.856 
aNo R50 calculation for the U ∩ C volume was made since the dose to the non-overlapping volume 
would be included in the calculation. 
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Figure 4-2 Dose volume histograms (left) and dose wash (right) for the mouse phantom whole liver 
irradiation plan, optimized with RAO. In both images, the liver (target) is shown in teal, body in 
yellow, and kidneys in red.  
 
 The resulting dose distribution for the Audrey RAO IMRT plan is shown in Figure 
4-3. This complex target image, with four dose levels (including 0 Gy) and 1 mm resolution, 
was closely replicated with RAO using a total of 551 apertures with a mean size of 2.4 x 2.4 
mm. Due to the high number of small fields, this corresponds to an estimated delivery time 
of approximately 18 minutes (after applying the output and off-axis factors presented in the 
following section). While this would be impractically high for a single beam of a mouse SOC 
plan, it is certainly feasible for delivery as a proof-of-concept. 
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Figure 4-3 (Left) Target image for the Audrey Hepburn plan, with 4 dose levels of 0, 2, 4, and 6 Gy. 
(Right) Optimized dose distribution from RAO with 1 mm beamlet and minimum aperture size. The 
optimized plan used 551 apertures with an average size of 2.4 mm. 
 
4.3.2 Beam Commissioning 
The absolute output of the SmART was 0.461 cGy/mAs, and the measured output 
factors are shown in Figure 4-4. A logarithmic curve was fit to the average measurements for 
field sizes 2.5 to 25 mm with an R2 value of 0.9916. Since the output dropped significantly 
for 1 mm fields and a simple curve could not closely fit all data points, a separate logarithmic 
equation was used for fields 1 to 2.5 mm. These relationships are used to scale each aperture 
by output factor based on its equivalent square field size. The smallest field size for which 
the output could be reliably measured with film was 1 mm, for which the output factor was 
0.747 ± 0.025. Therefore, although the orthogonal SOC design is theoretically capable of 
achieving smaller aperture sizes, for now the minimum beamlet size for SOC-based IMRT is 
limited to 1 mm. This inconsistency in submillimeter field dosimetry is likely the result of 
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slight leaf positioning errors, which have a large effect on small field sizes due to occlusion 
of the ~3 mm diameter focal spot.  There may also be error resulting from an inhomogeneous 
focal spot distribution, which has been observed in previous studies126 and will be discussed 
in a later section. 
 
Figure 4-4 Measured output factors (average and standard deviation shown for 4 measurements) 
for the SmART system, calculated as a fraction of the full 26 mm SOC field. 
 
Simplified off-axis factor measurements for field sizes 5, 2.5, and 1 mm are given in 
Table 4-3, averaged over nine SOC field regions for comparison, and the calculation process 
is illustrated in Figure 4-5 for 2.5 mm fields. The highest output was measured in the center 
of the SOC field for all three field sizes and was therefore the reference point for all other 
region measurements. The minimum and maximum (excluding the center) output factors 
were measured in the same SOC field regions for the 2.5 and 1 mm fields, but differed for the 
5 mm field, although the effect is minimal for this larger field size. The full interpolated maps, 
such as the one shown in Figure 4-5, right, are used for the final off-axis aperture scaling. 
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Table 4-3 Simplified off-axis factor measurements for 1, 2.5, and 5 mm square SOC fields on the 
SmART system, averaged over nine equal regions for comparison 
Off-Axis Factors (shown according to SOC field location) 
1 mm 2.5 mm 5 mm 
.70 .70 .65b .94 .96 .91b .97 .99 .99 
.75 1.00 .70 .96 1.00 .93 .98 1.00 1.00a 
.70 .80a .65b .93 .97a .91b .96b .97 .97 
aMaximum off-axis factor (excluding the center region) 
bMinimum off-axis factor 
 
 
Figure 4-5 The 2.5 mm field off-axis dose film map (left), mean dose measurement map (center), and 
final interpolated off-axis factor map (right). 
 
The measured PDD curves for square field sizes 1 to 40 mm are plotted in Figure 4-6, 
along with the matched energy spectra curves. Each spectrum is a weighted combination of 
two to three of the 40 candidate beams. The average maximum and mean differences 
between the measured and matched PDD curves were 4.47 ± 0.30% and 1.71 ± 0.18%, 
respectively. 
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Figure 4-6 Measured percent depth dose curves for different field sizes on the SmART (solid lines) 
and for the energy spectra optimized to match each measured curve (dashed lines). 
 
The flatness measurements for a 40 mm square field at depths of 2 mm, 2 cm, and 4 
cm are given in Table 4-4. Since all mean dose variations were below 5%, as well as the 
maximum variations at 2 mm depth, field flatness was not factored into our treatment 
planning process at this point. However, there were some maximum variations of over 5% 
at 2 cm and 4 cm depths. Since this may lead to non-negligible errors in our dose prediction, 
the field flatness will be further characterized and incorporated at the next level of planning 
system commissioning. 
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Table 4-4 Field flatness for a 40 mm square field on the SmART system 
Field Flatness (% variation, 40 mm field) 
 2 mm depth 2 cm depth 4 cm depth 
Direction Max Mean Max Mean Max Mean 
X 4.96 1.62 5.45 1.72 8.20 2.57 
Y 4.52 1.46 4.99 1.75 6.98 1.92 
 
4.3.3 Dose Recalculation 
For the Audrey plan dose recalculation assessment, the five plans optimized with 
each dose matrix (calculated for energy spectra tuned to 1, 3, 5, 10, and 20 mm field sizes) 
all selected at least two apertures of each closest equivalent square field size. The most 
common aperture size selected for each plan was 1 mm (66.8 ± 1.0%). This decreased with 
increasing field size, with a least common aperture size of 20 mm (0.6 ± 0.1%). The difference 
between the optimized and recalculated dose for each plan is shown in Figure 4-7 (upper), 
and the mean and maximum dose deviations, as well as the complete aperture size 
breakdown, are given in Table 4-5. 
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Table 4-5 Error comparison for plans optimized with different dose calculation spectra 
Optimization 
Dose Matrix 
(energy spectrum 
field size, mm) 
Optimized Dose – Recalculated Dose 
(absolute voxelwise comparison, % of maximum dose) 
Mean Maximum 
1 1.2 11.0 
3 3.0 16.0 
5 3.4 14.7 
10 3.1 9.7 
20 3.2 9.7 
 
The spatial distribution of the dose deviations is intuitive, with most of the error 
arising from the largest apertures in the 1 mm optimization and from the smallest apertures 
in the 20 mm optimization, while the 5 mm optimization shows a mix of both. The 1 mm 
optimized plan had a mean dose deviation of only 1.2% of the maximum dose, compared to 
≥3% for the other plans, likely because the majority of apertures were closest to this field 
size. The 10 and 20 mm optimized plans had the lowest maximum dose deviation of 9.7%, 
despite these field sizes making up only ~2.2% and ~0.6% of the total apertures, 
respectively. The 5 mm optimized plan had the highest mean deviation (3.4%) and the 3 mm 
plan had the highest maximum deviation (16.0%), which suggests that “compromising” with 
one of the middle aperture sizes may not be a good strategy. Given the computational power 
available, it is feasible to instead perform this initial optimization in parallel for all field sizes, 
perform the aperture-specific dose recalculation for each, and select (either manually or 
automatically) the dose distribution that best meets the planning objectives. 
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Figure 4-7 (Upper) Difference from the recalculated (field size-specific) dose for each optimization 
spectrum. (Lower) Dose optimized with the 1 mm field calculation spectrum (left), difference 
between the optimized dose and the recalculated dose, with a mean of 1.2% and maximum of 11.0% 
of the maximum plan dose (middle), difference between the optimized dose and the dose after 
reoptimization of the aperture weightings, with a mean of 1.2% and a maximum of 7.3% of the 
maximum plan dose (right). All dose distributions are shown at the target depth of 2 mm. (Dopt: 
original optimized dose; Drecalc: optimized dose recalculated based on aperture size; Dreopt: dose after 
reoptimization of aperture weightings) 
 
For the same test plan, the maximum difference between the original optimized dose 
(for 1 mm field size) and the recalculated dose was reduced from 11.0% to 7.3% of the 
maximum dose after reoptimization of the aperture weightings. The mean difference was 
maintained at 1.2%. These differences in dose distribution are shown in Figure 4-7 (lower). 
4.4 Discussion 
 The gap between human radiotherapy and preclinical animal studies has widened 
with the utilization of IMRT and other more sophisticated radiotherapy techniques including 
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4π radiotherapy. The increasing discrepancy in dose conformality can adversely impact the 
ability to translate animal studies to effective human trials. Due to a difference in size of one 
to two orders of magnitude, direct translation of the MLC used in human radiation therapy 
has met insurmountable engineering difficulties. In this study, we describe an alternative 
approach using a sparse orthogonal collimator for small animal IMRT. With the RAO SOC test 
cases, we demonstrated the ability to create highly conformal plans with concave and 
complex targets.  
It is evident from our beam commissioning measurements that the accurate 
characterization of small, off-axis fields is currently the limiting factor in terms of the 
minimum SOC aperture size. However, some of the main sources of error with these 
measurements are due to fundamental limitations of the SmART system itself and the 
temporary gantry mounting of the prototype SOC (described in Chapter 5), rather than the 
SOC design. Despite our best effort, there are some challenges mounting the SOC onto the 
SmART system gantry, causing slight misalignment with each installation. Even with leaf 
position re-calibration, the misalignment can introduce detectable residual error for fields 
smaller than the 3 mm diameter focal spot. While the SmART system does have a smaller 
focal spot option, the low output would lead to prohibitively long treatment times. 
 Even with perfect SOC alignment, the dosimetry of submillimeter field sizes would 
likely still be a challenge. Tryggestad et al performed a pinhole experiment with a similar 
source (225 kVp, 3 mm large focal spot) on the SARRP and found that the focal spot had a 
highly inhomogeneous intensity, significantly affecting the dose distribution from a 0.5 mm 
aperture126. These effects were much less significant for 1 mm fields, resulting in only slight 
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asymmetry. In order to reduce the minimum SOC aperture size below 1 mm, we would need 
to fully characterize the large focal spot fluence distribution and incorporate this into our 
dose calculation engine for more accurate small field dose predictions. 
Despite these uncertainties, the SOC is better suited for small animal radiotherapy 
than the MLC. In addition to the simplified hardware design, the SOC has advantages in terms 
of the optimization algorithm. While the MLC can conform to more arbitrary shapes, the SOC 
is seemingly limited in the complexity of apertures. However, this limitation is advantageous 
in solving the direct aperture optimization problem using the rectangular basis, since the 
dose degradation during the fluence map to MLC aperture conversion is avoided. This results 
in high quality plans and in some cases, such as the U target plan, more homogeneous and 
conformal PTV doses. Our analytical rectangular direct aperture optimization method is 
distinctly different from previous “jaws-only” optimization approaches127,128 using a 
stochastic simulated annealing method, which is slow and cannot search all available 
apertures.  
 Also, unlike with human treatments, trained dosimetrists and medical physicists are 
unaffordable in preclinical studies. Therefore, any small animal treatment planning system 
must be highly automated in order to be a realistic and desirable alternative to current 
methods. Although the target and avoidance structures, if any, would still need to be 
contoured, the rest of the proposed planning system requires very limited user input. With 
the use of automated beam selection, followed by rectangular aperture optimization and 
system-specific plan post-processing, high quality treatment plans can be created for SOC 
delivery without any special training or lengthy planning process. 
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4.5 Conclusions 
 By using advanced optimization techniques, complex IMRT plans were achieved 
using a simple dose modulation device. Beam commissioning data was incorporated into the 
treatment planning process to more accurately predict the resulting dose distribution. This 
platform substantially reduces the gap in treatment plan quality between clinical and 
preclinical radiotherapy, potentially increasing the value and flexibility of small animal 
studies.  
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5 SOC HARDWARE 
DEVELOPMENT AND 
COMMISSIONING 
5.1 Introduction 
 As described in Chapter 4, one of the main limitations in the clinical translation of 
small animal radiotherapy studies is the major discrepancy in irradiation techniques99. To 
deliver analogous treatment to small animals, the development of a small animal IMRT 
platform is necessary. Such a platform requires two developments, the first being a planning 
approach based on inverse fluence map optimization, such as the Rectangular Aperture 
Optimization (RAO) based treatment planning system detailed in Chapter 4. The second is a 
dose modulation device suitable for the small animal scale.  
The majority of small animal radiotherapy systems have been limited to stationary 
collimators, with a few exceptions. At Stanford University, a variable hexagonal aperture 
collimator was developed to achieve beam diameters up to 102 mm22. The University of 
Western Ontario developed motorized orthogonal jaws for their micro-CT/RT system, with 
characterization focused on 2 to 30 mm field sizes23. A binary micro-MLC (bmMLC) has also 
been developed by the University of Wisconsin-Madison24. Unlike the dynamic MLC with a 
continuous range of leaf positions, the bmMLC leaves are either open or closed, similar to the 
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collimator design for the Tomotherapy system129. However, this system is limited by 
excessive leakage (5.4% interleaf leakage, 1.7% average transmission) and long delivery 
times. While all of these devices enable more conformal treatment delivery, none are optimal 
for small animal IMRT. 
More recently, a Motorized Variable Collimator (MVC) has become commercially 
available for the Small Animal Radiation Research Platform (SARRP) (Xstrahl Inc., Suwanee, 
GA), which uses two sets of focused, orthogonal tungsten jaws. Very preliminary efforts using 
the MVC for jaws-only small animal IMRT have been presented from the Institute of Cancer 
Research, London130. This approach generates IMRT fluence maps first and then converts 
them to rectangular apertures. This process is known to degrade the dosimetry, which 
worsens when the shape and number of apertures is limited. Furthermore, the MVC is 
fundamentally limited by its inability to create asymmetric apertures, requiring the use of 
couch movements to deliver off-axis fields. This excessive couch translation introduces 
significant potential for motion errors and increased delivery times, which are already 
lengthy because only one aperture can be delivered at a time.  
Clinical dose modulation devices have been developed to exploit the unique 
advantages of bi-directional collimation while also providing the flexibility of an MLC. In 
studies on the commissioning of a dual-layer micro MLC for clinical radiotherapy systems, 
the additional layer of leaves significantly reduced the leaf-end transmission131,132, which can 
be as high as 30% for a typical single-layer MLC133. The ability to collimate fields in both 
directions with the second orthogonal layer MLC layer also enables higher resolution than a 
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standard single-layer MLC, for which the resolution perpendicular to leaf motion is 
determined by the physical leaf width. 
The Sparse Orthogonal Collimator (SOC), with four pairs of double-focused 
orthogonal leaves, maintains the simplicity of a jaws-only system while achieving flexibility 
closer to that of a dual-layer MLC, as well as increased delivery efficiency. This makes the 
SOC ideal for small animal dose modulation when used in combination with the RAO-based 
treatment planning system detailed in Chapter 4. In this chapter, the complete design and 
fabrication of the SOC hardware is presented, as well as the software development and full 
system commissioning and testing.  
5.2 Methods 
5.2.1 SOC Design 
In order to deliver rectangular apertures, theoretically only two pairs of orthogonal 
leaves are required (essentially “jaws-only” IMRT). However, increasing the number of 
leaves increases the delivery efficiency, as it enables the dose to certain regions of the fluence 
map to be delivered in parallel, as previously mentioned. Increasing this to more than two 
leaves per bank greatly increases the complexity of the system while providing only minor 
improvements in efficiency, as previously shown114. Therefore the preclinical SOC designed 
in this study features two leaves per bank. 
This orthogonal system design is ideal for a miniaturized small animal system as the 
deliverable aperture resolution is dependent on the leaf motion step size rather than the leaf 
width. However, the simplicity of the SOC design requires that the two sets of orthogonal 
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collimator leaves have slightly different source-to-leaf distances, which could cause the 
delivered fluence rectangles to have an asymmetric penumbra. This is mitigated with a 
double-focused leaf design, where the leaves have curved geometry and move along an arc 
that matches the beam divergence. While the general SOC geometry is feasible for use with 
a variety of irradiators, the design detailed in this study was tailored to the X-RAD SmART 
small animal image-guided irradiation system at UCLA. Computer-aided design (CAD) 
models for all SOC system components were created using Autodesk Inventor (Autodesk, 
Inc., San Rafael, CA). 
Designs for the double-focused SOC leaves are shown in Figure 5-1. The radii of 
curvature were chosen for a source-to-leaf distance (to the top of the upper leaf) of 14.94 
cm, with 3 mm thick leaves and a gap of 0.5 mm between upper and lower leaf sets to avoid 
collision. The leaves are 3 mm thick to achieve >99.5% beam attenuation based on 
preliminary transmission measurements with the same tungsten alloy (95% W, 3.5% Ni, 
1.5% Fe; density of 18 g/cm3). The depth of the tongue and groove is 0.2 mm in order to keep 
the leaves interlocked without significantly affecting the penumbra. The heights of the 
tongue and groove are 1.4 and 1.6 mm, respectively. These dimensions are ideal firstly 
because a 0.1 mm tolerance is necessary on each side of the tongue for smooth movement. 
Also, this means that both leaves have a total of 1.4 mm of tungsten extending the 0.2 mm of 
the tongue and groove joint and will therefore have the same x-ray attenuation, preventing 
uneven SOC aperture penumbras. Each leaf also has a 1.35 mm thick, 1.45 mm wide outer 
tongue that slides along rails in the SOC housing for added leaf stability. These tongues are 
along the top edge for upper leaves and bottom edge for lower leaves. Each upper and lower 
leaf pair also has a mirroring pair for the opposing leaf bank, with the leaf connector tab on 
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the opposite end, enabling inter-digitation of opposing tongue and groove joints. Therefore, 
the geometry for each of the eight leaves is unique.  
 
Figure 5-1 Leaf designs for the SOC, with dimensions shown in millimeters. Upper and lower leaf 
sets feature different radii of curvature and different geometry for the outer stabilizing tongues 
(along the top/bottom for upper/lower leaves, respectively). Each tongue and groove pair also has a 
mirroring pair with the tab on the opposite end. 
The CAD model for the rest of the SOC system is shown in Figure 5-2. A custom rod 
with clevis and pin attaches the tab on each leaf to a stepper motor, which screws into a 
support structure in the housing. The outer leaf tongues slide along upper or lower rail 
systems for stability. A column of small (4 mm) tungsten cubes at the intersection of each 
orthogonal leaf bank shields the outside corners of the primary collimator field (4 x 4 cm at 
isocenter), which is larger than the SOC field (2.6 x 2.6 cm). The top of the housing features 
a detachable cable guide for the motor wires, which attach to a common socket at the back 
of the SOC. The housing top also has an adapter for mounting the system to the primary 
SmART collimator. The adapter is designed for a very tight fit onto the collimator (which 
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unfortunately has no other features to use for mechanical attachment) with a screw clamp 
for extra support. Figure 5-3 shows the whole SOC system mounted onto the SmART gantry.  
 
Figure 5-2 CAD model of the SOC. (A) Leaves connected to motor shafts with 3D printed rods and 
pins. (B) Stepper motor pair screwed into housing. (C) Outer leaf tongues slide along rails in housing. 
Shown in each corner of the SOC field are tungsten inserts for shielding the corners of the larger 4 x 
4 cm primary collimator field. (D) All four orthogonal leaf banks. (E) Covers slide into the housing 
over each motor bank. (F) Main housing top attached, with mount for square primary collimator. (G) 
Complete SOC system with adapter to the primary 4x4 cm square SmART collimator. The collimator 
slides tightly into the adapter with a screw clamp for added support. The C-shaped attachment 
around the adapter guides the motor cables to the main socket on the back of the SOC. 
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Figure 5-3 The SOC mounted onto the gantry of the SmART system via the primary 4 cm fixed 
collimator. 
 
5.2.2 SOC Fabrication 
The four pairs of leaves for the SOC were machined out of a Class 3 tungsten alloy 
(95% W, 3.5% Ni, 1.5% Fe; density 18 g/cm3) by a machine shop (Figure 5-4). While tungsten 
is considerably more difficult to machine than a softer metal such as copper, its high density 
is necessary for achieving the desired attenuation with leaves thin enough for the small scale 
of the SOC.  
 
Figure 5-4 Machining of the prototype tungsten alloy leaves for the SOC. 
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The main housing for the SOC, shown in Figure 5-5, was fabricated out of plastic with 
stereolithography 3D printing (Formlabs Form 2, White Resin). The primary collimator 
adapter, which attaches the SOC to the 4 cm square collimator of the SmART system, was 
also 3D printed. Tungsten cubes (4 mm) were inserted into the housing between 
perpendicular leaf banks for shielding, since the primary collimator field is larger than the 
open SOC field. 
 
Figure 5-5 3D printed SOC housing: main SOC leaf housing (upper left); outer leaf tongues slide along 
housing rails (upper middle); leaves attached to motors with 3D printed rods and pins (upper right); 
housing with all 8 SOC leaves (lower left); housing top with opening for 4 x 4 cm primary collimator 
and cable guide attachment (lower middle); housing for Arduino board and motor driver boards 
(lower right). 
 
The SOC leaves are driven by captive stepper motor linear actuators (Haydon Kerk 
Motion Solutions, Size 8) which have a maximum speed of over 4 cm/sec and resolution of 
0.04 mm/step. Rotary encoders are installed for precise leaf position verification with 
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resolution of <0.02 mm. The motors are wired to stepper motor driver boards (EasyDriver 
V4.5), which are controlled with an Arduino Mega 2560 microcontroller. These boards 
enable microstepping with the motors to achieve even finer motor control of 0.005 mm per 
eighth step. 
5.2.3 SOC Control Software 
A graphical user interface (GUI) has been developed in Python for controlling the SOC 
leaf motion (Figure 5-6). The leaves can be moved by either manually dragging the leaf 
images in the GUI or by loading an aperture sequence from a JavaScript Object Notation 
(JSON) file. The aperture sequences can also be created or edited within the GUI and saved 
as a JSON. Leaf motion commands are then sent over a serial connection to the Mega 2560 
board, which is loaded with an Arduino program. This program evaluates the new leaf 
positions for any potential collisions (and sends an error if necessary) then moves each 
motor the necessary number of steps, using the encoder feedback for verification. The 
controller proceeds with the treatment once it receives confirmation of successful leaf 
repositioning.  There is also a leaf calibration feature, which allows the user to set a new 
“zero” position for the leaves.  
These aperture sequence files are created in MATLAB following fluence map 
optimization with RAO and plan post-processing, as described in Chapter 4. The apertures 
are first shifted to the center of the SOC field, if necessary. The aperture boundaries are 
converted to a set of eight leaf positions, which are then written to a JSON file for loading into 
the SOC controller GUI. The couch angle (optional using a 3D printed rotating couch mount, 
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shown in Figure 5-9), gantry angle, and dwell time are also included, along with an option 
for manual or automatic sequence progression. 
 
Figure 5-6 Graphic user interface for SOC control, with an aperture sequence loaded from a 
JavaScript Object Notation (JSON) file. Apertures can be edited and saved using the Sequence Item 
Editor shown. Leaves can also be controlled by dragging the gray “leaves” on the left. The “Calibrate 
Leaflet Positions” feature can also be used to set a new leaf “zero” position. 
5.2.4 SOC Installation 
Prior to initial installation and commissioning of the SOC, the SmART calibration 
software was used to verify the source-axis-distance (SAD), magnification factor, isocenter 
location, and center of the detector panel. A Winston-Lutz map of the primary 4 cm square 
collimator was also created using the system calibration software to factor into the overall 
system alignment measurements. For this test, PXI’s standard 3 mm calibration BB phantom 
is first moved to the treatment isocenter. Using the projection on the flat panel detector, the 
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calibration software then measures the offset between the center of the collimator field and 
the treatment isocenter over a full gantry rotation. 
    
Figure 5-7. SOC installed on SmART system, attached to the 4 x 4 square primary collimator. 
 
The SOC is installed on the head of the SmART by attaching it to the primary 
collimator with a 3D printed sleeve and clamp (Figure 5-7). Cabling from the electronics 
(driver boards and microcontroller) to the SOC is fed through a side hole in the cabinet, with 
shielded cable used inside the cabinet for noise suppression. The leaf positions are then 
manually calibrated using the fluoroscopy mode of the SmART calibration software. The 
leaves are extended individually to measure the position of the x- and y-axis of the SOC, 
determined by the inner edges of the upper and lower leaves, respectively (Figure 5-8, 
upper). The leaves are then moved the appropriate distance from each axis for an open field, 
based on the desired field size at isocenter (maximum 26 x 26 mm) and the measured 
magnification factor of the system to the flat panel detector. Using the calibration module of 
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the GUI, these leaf positions are saved as the new “zero” positions for the motor encoders 
(Figure 5-8, lower).  
 
Figure 5-8 SOC leaf position calibration procedure using the fluoroscopy mode of the SmART system 
calibration software. (Upper) SOC axes are determined from the inner leaf edges. (Lower) open leaf 
positions are set to the desired distance from each axis and the new calibration is saved with the SOC 
GUI. 
 
To verify that the leaves are properly aligned to each other and at the correct field 
size, a simple grid pattern is then delivered to film and the resulting dose distribution is 
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analyzed. A custom couch-mounted 3D printed film holder is used with standard-sized film 
squares for reproducible alignment. 
5.2.5 SOC Commissioning Measurements 
After initial installation, the mechanical accuracy and reproducibility of the SOC were 
evaluated. The AAPM Task Group 50 report, “Basic Applications of Multileaf Collimators”134, 
includes a section for MLC Acceptance Testing, Commissioning, and Safety Assessment 
describing methods for performing many of the necessary QA tests and measurements for a 
new MLC. Although some procedures could not be directly translated due to hardware 
limitations (e.g. no light field or collimator rotation), a series of adapted tests were 
performed. All film measurements were performed with Gafchromic EBT3 film (lot 
#10161801) and analyzed with the FilmQA Pro software. 
First, the mechanical axes alignment and rotational stability of the SOC were verified. 
Alignment of the SOC with the gantry axis was measured by exposing the same film, placed 
at the system isocenter, with both the open SOC field and the 40 mm square primary 
collimator alone and measuring the distance between field center points. The x- and y-axes 
for each collimator were defined by the center of the 50% isodose distribution. This was 
repeated at 1 cm below isocenter to reveal any angular misalignment.  The rotational 
stability and effects of the extra SOC weight on the gantry alignment were then evaluated by 
repeating the Winston-Lutz Test previously described with the SOC installed on the primary 
collimator. A spoke shot pattern was also created for visual verification by exposing film 
perpendicular to the rotational axis with a 1 mm slit field at 45° increments. 
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To measure the leaf positioning accuracy, a series of abutting rectangular fields (26 x 
4 mm) were delivered to film, and the dose at the matchlines between fields was analyzed. 
This was repeated for both upper and lower leaf sets (i.e. horizontal and vertical). A grid 
pattern was then delivered to verify the alignment between the upper and lower leaf sets, 
and a pixelwise comparison was performed between the 50% isodose distribution and the 
intended pattern. This grid pattern was delivered several times in a row to assess the leaf 
position repeatability by measuring the distance between 50% isodose lines. Grids were also 
compared between different instances of SOC installation and calibration to assess the 
calibration accuracy.  
The transmission through the center of each leaf (mid-leaf), between each tongue and 
groove joint (inter-leaf), and between opposing leaf faces closed at the field midline (closed 
leaf) were also measured using film. Measurements were performed for both upper and 
lower leaf tiers, with the four leaves closed at the midline of the field. This was repeated at 
gantry angles of 90°, 180°, and 270° to identify any changes in leakage with potential leaf 
shifts during rotation. Transmission was calculated as the maximum leakage dose divided 
by the maximum open field dose for the same exposure time. The penumbra, calculated as 
the distance from 80 to 20% of the maximum dose, was determined for upper and lower leaf 
faces and edges (tongue and groove) by exposing film with each leaf extended individually 
to the midline. Because the leaves are double-focused, the leaf face penumbra should not 
change significantly with leaf position. To verify this, the penumbra was also measured for 
central square apertures with lengths of 26 (open field), 20, 10, and 5 mm at depths of 2 and 
20 mm. 
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5.2.6 Dosimetric Testing 
 Three different test plans, either analogous (a highly concave target) or identical 
(the mouse whole liver and complex 2D “Audrey” plans) to those evaluated in Chapter 4, 
were delivered for end-to-end testing of the SOC treatment planning and delivery process 
(Table 5-1). All plans were delivered with a 225 kVp, 20 mA x-ray beam with 0.32 mm added 
copper filtration.  
 For the first experiment, the SOC’s ability to deliver a 3D concave dose distribution 
was demonstrated. This type of plan is a hallmark of IMRT and an AAPM standard for IMRT 
commissioning135. A C-shaped target plan was created for a simple 3D printed block 
phantom (3.5 x 3.5 x 2 cm, Figure 5-9, right) using eight equally spaced coplanar beams, and 
film was inserted in the center (mid-axial plane) of the phantom to analyze the dose 
distribution perpendicular to the rotational axis. 
 
Figure 5-9 (Left) Mouse phantom modeled from mouse CT data and 3D printed with a flexible, tissue-
equivalent material and a mid-coronal split for film measurement. Phantom is shown on the 
previously mentioned rotating couch mount. (Right) 3D printed block phantom for axial dose 
measurements. 
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For the second experiment, A 3D printed mouse phantom (Figure 5-9, left) modeled 
from mouse CT data was used to demonstrate a realistic application for the SOC, as described 
in Chapter 4. Mouse liver and kidney structures were transferred from a contrast-enhanced 
mouse CT, and the liver was targeted with a dose of 10 Gy using 5 beam angles optimized 
with the 4π algorithm9,10,12-15,26-28,85,122. Film was inserted between the two phantom halves 
for dose measurement.  
To demonstrate the ability to optimize and deliver complex 2D dose distributions 
with the SOC, a third test plan with 1 mm resolution and three dose prescription levels (2, 4 
and 6 Gy) was delivered. This plan, optimized to resemble an image of Audrey Hepburn as 
shown in Chapter 4, includes apertures with equivalent square sizes ranging from 1 to 20 
mm, with a total of 551 apertures and an average aperture size of 2.35 mm. While this plan 
is arguably more complex than any foreseeable small animal applications for the SOC, it was 
developed to visualize the full IMRT capabilities of the system.  
Table 5-1 SOC test plan parameters 
Test plan 
# of 
beams 
Target dose 
levels 
Average # 
apertures 
per beam 
Average 
aperture 
size (mm) 
Delivery 
time 
(min)a 
Film 
measurement 
set up 
C-shaped 
target 
8 1 (10 Gy) 76.6 3.5 ± 1.4 ~14 
Cube phantom 
(mid-axial plane) 
Mouse 
liver 
5 1 (10 Gy) 101.6 1.8 ± 0.8 ~19 
Mouse phantom 
(mid-coronal 
plane) 
Audrey 
Hepburn 
1 3 (2, 4, 6 Gy) 551 2.4 ± 2.1 ~19 
Below 2 mm 
solid water 
aApproximate delivery times were based on a 225 kV, 20 mA beam with an output of 0.461 cGy/mAs. 
The average leaf motion time was ~400 ms/aperture, accounting for ~20% of total delivery time. 
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 For the C-shaped target and mouse phantom liver plans, the maximum, mean, and 
minimum structure doses were compared between the measured film dose and the 
calculated, or intended, dose distribution. A pixelwise comparison was performed for the C-
shaped plan and mouse liver plan structures to assess the deviation from the intended dose 
for each pixel, with the maximum and mean absolute deviations reported. Gamma analysis 
was also performed to compare the calculated and measured dose distributions, for which 
the typical clinical criteria are 3% dose-difference and 3 mm distance to agreement (DTA)136. 
In previous studies, these criteria have been adapted for small animal radiotherapy to 4% 
and 0.3 mm to account for the approximate order of magnitude difference in imaging 
resolution137,138. Thus, 4%/0.3 mm criteria was used for analysis in this study. 
5.3 Results 
5.3.1 SOC Commissioning 
The agreement between the SOC and primary collimator axes at the treatment 
isocenter was within 0.66 mm in the x-direction, and there was no measured offset in the y-
direction. At 1 cm below isocenter, the measured offsets were 0.40 mm and 0.66 mm in the 
x- and y-directions, respectively. This suggests an angular misalignment between the SOC 
and the primary collimator of approximately 1.5° in x and 3.8° in y. These measurements are 
in close agreement with the Winston-Lutz tests, which showed a difference between the two 
collimators of 0.53 mm and 0 mm in x and y at the treatment isocenter. Over the full gantry 
rotation, as shown in Figure 5-10 (left), the maximum deviation of the SOC field center from 
the treatment isocenter was 1.04 mm in x (-1.04 to +0.88) and 1.65 mm in y (-1.65 to +0.1).  
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However, these shifts are reduced when the misalignment of the primary collimator is 
factored in, suggesting that the rotational stability of the SOC itself is within 1 mm in both 
directions. This means that this error can be reduced by defining virtual isocenter 
corrections in the SmART system software, which will adjust the couch to make up for 
systematic alignment error. This rotational stability is also evident in the spoke shot pattern 
in Figure 5-10 (right).  
 
Figure 5-10 (Left) The measured offsets between the SOC field center and treatment isocenter at 
each projection angle in the x (blue) and y (red) directions are shown with solid lines. The difference 
between the offsets with the SOC (mounted on the primary collimator) and the primary collimator 
alone (S40) are shown with dotted lines. (Right) Spoke shot pattern from 1 mm slit SOC fields 
delivered at 8 equally spaced angles, measured perpendicular to the rotational axis and shown with 
a 2 Gy minimum dose cutoff. 
 
The upper and lower leaf abutting fields patterns are shown in Figure 5-11 (left, 
center). Averaged over 6 line profiles, the maximum deviations from the average dose were 
18.8 ± 3.1% (mean 4.4 ± 0.5%) and 15.5± 2.9% (mean 1.9 ± 0.2%) for the upper and lower 
leaf patterns, respectively. These measurements are within the AAPM Task Group 50134 
guideline that dose deviations >20% are indicative of leaf misalignment. 
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One of the measured grid dose patterns is also shown in Figure 5-11, and the accuracy 
and repeatability measurements are given in Table 5-2. The pixelwise comparison of the 
50% isodose lines for nine grid patterns (from three different calibrations) with the ideal 
binary grid pattern had a match of 94.4%, with maximum deviations of 0.5 mm. When five 
sequentially delivered grid patterns were compared to one another to assess the intra-
calibration repeatability, there was a slightly lower pixel match of 93% with a maximum 
deviation of 0.5 mm. This maximum deviation increased slightly to 0.8 mm for grids 
compared between three different SOC leaf calibrations. 
 
Figure 5-11 Abutting field film patterns for the upper (left) and lower (center) leaves, normalized to 
the average field dose. (Right) One of the alignment verification grid patterns delivered with the SOC, 
normalized to the maximum dose. 
 
Table 5-2 Leaf positioning accuracy and repeatability measurements 
 # of Grids % Pixel Match Maximum Deviation 
Accuracy 
9 
(3 calibrations) 
94.4 ± 0.01% 0.5 mm 
Intra-calibration 
repeatability 
5 
(same calibration) 
93% 0.5 mm 
Inter-calibration 
repeatability 
3 
(3 calibrations) 
91% 0.8 mm 
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The mid-leaf transmission through a single layer of SOC leaves was extremely low, 
with a maximum measurement of only 0.15 ± 0.05% of the full dose and a mean of 3x10-5% 
(Table 5-3). The inter-leaf leakage was 0.27 ± 0.05%, which is well below the AAPM 
recommended maximum of 3%134. There was no statistically significant difference in inter-
leaf leakage between measurements at the four major gantry angles, with a maximum 
difference of +0.07%, suggesting minimal shifting of the SOC leaf pairs with gantry rotation. 
The maximum closed leaf transmission, measured along the central matchline of all four 
leaves, was 7.27 ± 3.40%. The rotational difference in closed leaf transmission was again not 
statistically significant, with a maximum difference of +1.16%. This leakage is likely due to 
geometrical imperfections in the machined leaf faces and the 3D printed SOC housing, but is 
still well within the AAPM recommendation of <25%134. Also, this transmission is irrelevant 
for SOC plan delivery, since it can be completely mitigated by using off-axis positions for the 
upper and lower closed leaf positions. 
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Table 5-3 SOC leaf transmission and penumbra measurements 
Transmission (% full field dose) 
 Mid-leaf (n=8) Inter-leaf (n=12) Closed leaf (n=4) 
Maximum 
transmission (0°) 
0.15 ± 0.05% 
(mean 3x10-5%) 
0.27 ± 0.22% 7.27 ± 3.40% 
Maximum 
rotational variation 
(0° - 270°) 
- +0.07% +1.16% 
AAPM TG 50 
recommendation134 
<2% <3% <25% 
Penumbra (80 to 20% dose distance, mm) 
 
Upper (n=12) Lower (n=12) 
Average 
Tongue Groove Tongue Groove 
Leaf edge 0.79 ± 0.04 0.81 ± 0.06 0.82 ± 0.04 0.75 ± 0.07 0.79± 0.05 
Leaf face 0.80 ± 0.05 0.80 ± 0.1 0.80 ± 0.08 
Square field 
size (n=4): 
26 mm 20 mm 10 mm 5 mm Range 
2 mm depth 0.86 ± 0.09 0.97 ± 0.10 0.80 ± 0.07 0.80 ± 0.13 0.17 
20 mm depth 1.56 ± 0.24 1.26 ± 0.25 1.15 ± 0.14* 1.00 ± 0.12** 0.55 
*Significantly different from the 26 mm field penumbra (2-tailed t-test, 5% significance level) 
** Significantly different from the 10 and 26 mm field penumbras (2-tailed t-test, 5% significance 
level) 
The leaf penumbra measurements are also shown in Table 5-3. There was no 
significant difference in penumbra between upper and lower leaf faces, upper and lower leaf 
edges, or tongue and groove leaf edges. The average leaf edge and face penumbras were 0.79 
± 0.05 mm and 0.80 ± 0.08 mm, respectively, which also had no significant difference. This is 
beneficial because although leaf edges are not used to form aperture boundaries in a typical 
SOC plan, they could theoretically be used without resulting in an asymmetrical field 
penumbra (for example, the delivery of two diagonal quadrants with a single leaf layer). For 
measurements at 2 mm depth, there was no significant difference in penumbra with leaf 
position for square apertures 5 to 26 mm, with a range of 0.17 mm. There was slightly more 
variation in penumbra at 20 mm depth, with a range of 0.55 mm and significant differences 
between several of the field sizes (5 vs 10 mm, 5 vs 26 mm, and 10 vs 26 mm). It should be 
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noted that the source-to-leaf distance of the SOC was extended after machining of the current 
leaves in order to achieve superior dosimetry at the treatment isocenter. Therefore the 
radius of curvature of these leaves is slightly less than it would be for a fully double-focused 
system, which would theoretically result in a more consistent leaf penumbra. However, 
based on the system and setup geometry, the measured penumbra range at 2 mm depth 
suggests a focal spot size of 2.6 to 3.1 mm. Since the reported diameter is approximately 3 
mm, the large focal spot is likely the main source of the measured penumbra. 
5.3.2 Dosimetric Testing 
Figure 5-12 shows the calculated (left) and measured (center) dose distributions for 
the C-shaped target plan. The gamma analysis with 4%/0.3 mm criteria revealed a pass rate 
of ~95% for pixels within the target structure, and 85% for the entire field shown. The 
maximum and mean absolute pixelwise dose differences were 4.12 and 0.59 Gy, respectively 
(Table 5-4), and the measured dose to the target had slightly higher maximum (15.8% of the 
prescription dose), mean (7.0%), and minimum (13.5%) doses. The 50% isodose lines are 
shown in Figure 5-12 (right), demonstrating excellent overall agreement between the 
calculated and measured dose distributions. 
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Figure 5-12 (Left) Calculated dose distribution of the C-shaped target plan perpendicular to the 
gantry rotation axis. (Center) Measured film dose distribution from the center of the solid water 
phantom for the C target plan delivered with the SOC. Both plans are shown with the same color scale, 
in units of Gy. (Right) A comparison of the calculated (yellow) and measured (blue) 50% isodose 
lines, with overlapping regions shown in red. 
The results of the mouse phantom liver test plan are shown in Figure 5-13, with the 
liver and kidney dose comparisons given in Table 5-4. The maximum measured liver dose 
was 13.0% higher than the calculated dose, the mean was 10.2% lower, and the minimum 
was 11.0% higher. As evident in the film dose distribution and isodose comparison shown in 
Figure 5-13 (C) and (D), the lower left portion of the liver was cut off due to slight phantom 
misalignment. The affected pixels were omitted from the liver dose analysis, and the 
measured dose distribution was rotated slightly to account for the setup error. For the 
unaffected pixels within the liver, the gamma analysis showed a high pass rate of 98.2%. The 
measured SOC plan was also able to significantly spare the dose to the kidneys (based on the 
location of the kidney contours in relation to the liver in the measurement plane) with 
maximum and mean doses of 0.43 and 0.24 Gy, respectively. These are only 4.3% and 2.4% 
higher than the calculated doses, and all pixels in the kidneys met the 4%/0.3 mm gamma 
criteria. 
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Table 5-4 Comparisons between the measured and intended dose distributions for the C-shaped 
target plan and the mouse phantom whole liver plana 
 
Structure Dose Deviations 
(measured – calculated) 
Pixelwise Dose Comparison 
Plan Structure Max Mean Min Max Diff Mean Diff 
Gamma 
Pass Rate 
C 
Target 
C 
+1.58 
(15.8%) 
+0.70 
(7.0%) 
+1.35 
(13.5%) 
4.12 
(41.2%) 
0.59 
(5.91%) 
94.9% 
Mouse 
Liver 
Liver 
+1.30 
(13.0%) 
-1.02 
(10.2%) 
+1.10 
(11.0%) 
3.50 
(35.0%) 
1.19 
(11.9%) 
98.2% 
Kidneys 
+0.43 
(4.3%) 
+0.24 
(2.4%) 
+0.11 
(1.1%) 
0.43 
(4.3%) 
0.24 
(2.4%) 
100% 
aMaximum, mean, and minimum dose differences written as [Gy (% prescription dose)]; Max and 
Mean Diff are absolute pixelwise dose differences; gamma analysis was performed with 4%/0.3 mm 
criteria for dose/distance 
 
 
Figure 5-13 (A) Mid-coronal view of the calculated dose for the mouse phantom whole liver plan 
(units of Gy). (B) The 5 optimal coplanar beam angles selected with the 4π algorithm. (C) Measured 
film dose from the mouse phantom, treated with the whole liver plan, at the plane shown in (A) (units 
of Gy). (D) A comparison of the calculated (yellow) and measured (blue) 60% isodose lines, with 
overlapping regions shown in red. Target structure was rotated to account for slight phantom 
misalignment, which also resulted in the truncated lower left portion of the target. 
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The calculated and measured doses for the 2-dimensional Audrey test plan are shown 
in Figure 5-14. The maximum and minimum measured film doses were both 1.1 Gy higher 
than the calculated dose distribution (12.2% of the maximum intended dose), with a mean 
pixelwise absolute dose difference of 1.6 Gy. Although this plan shows some discrepancies 
in absolute dose prediction for very small apertures sizes, the sources of which are discussed 
in Chapter 4, the spatial distribution is extremely similar to the calculated plan, validating 
the overall accuracy of the SOC hardware and control software. 
 
Figure 5-14 (Left) Calculated Audrey test plan with 4 dose levels and an average aperture size of 
2.35 mm. (Right) Measured dose distribution of the Audrey plan delivered with the SOC. Both plans 
are shown with the same color scale, in units of Gy. 
 
5.4 Discussion 
 In addition to the planning dosimetry capability of SOC for preclinical x-ray IMRT 
shown in Chapter 4, the engineering feasibility, fabrication, and delivery dosimetry 
performance of the SOC is demonstrated in this chapter. Compared to the MLC, we believe 
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that the SOC is better suited for preclinical applications. First of all, SOC resolution is 
independent of the leaf width in both collimation directions, avoiding the engineering 
challenge of further reducing the MLC leaf width. Consequently, the SOC has substantially 
fewer moving components than the MLC, making miniaturization feasible and more robust. 
SOC modulation resolution depends on leaf step size, which is determined by the stepper 
motors, and can therefore in theory be on the order of a micron. In practice, this mechanical 
resolution is limited by the resolution of the motor encoders and the accuracy of the housing 
fabrication, but is still well below a millimeter for the described SOC design. The current RAO 
formulation described in Chapter 4, however, does have a finite beamlet resolution due to 
the discretized nature of the rectangles, which does not take full advantage of the resolution 
capabilities of the SOC geometry. Further investigation of a multi-resolution approach must 
be conducted to better exploit this design. 
The SOC design is also advantageous over a conventional MLC because it makes 
closed leaf end transmission inconsequential. While this is significantly lessened with a dual-
layer MLC, this configuration still has a region of higher transmission where the closed leaf 
matchlines intersect. These matchlines are not necessary with the SOC, since it is possible to 
block the entire SOC field without even fully closing opposing leaf pairs. The maximum 
transmission in this SOC configuration would be from the photons in the center point of the 
field, passing through both upper and lower tongue and groove joints, which would only be 
approximately 0.07% based on our interleaf transmission measurements. In general, these 
low transmission levels are a major advantage of the SOC leaf design, with our measurements 
suggesting an average mid-leaf transmission through both layers of only about 0.02%. 
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Although the inherent delivery efficiency of the SOC design is lower than that of a 
typical MLC system, the ability to deliver two fields in diagonal quadrants simultaneously 
can potentially reduce delivery times by up to 50% compared to jaws-only IMRT. These 
reductions are even greater when we consider the added time from off-axis aperture couch 
shifts with a system like the motorized variable collimator. Also, the SOC aperture 
optimization can be easily tuned to select fewer, larger apertures for plans where short 
delivery times are a priority. Additionally, although currently the leaf repositioning time is 
~400 ms/aperture and accounts for approximately 20% of the overall delivery time, we 
believe there is significant room for reduction with more optimized leaf motion control. 
Overall, the preliminary results from the SOC are promising. The SOC leaves have a 
very consistent penumbra, varying by only 0.17 mm with leaf position at 2 mm depth and 
with no measurable difference between the upper and lower sets, despite the current 
discrepancy between the beam divergence and leaf radii. Using just the quick, simple leaf 
position calibration procedure described, abutting field patterns were delivered with <20% 
dose difference at the matchlines, as recommended by AAPM guidelines134. In the C-shaped 
target experiment, the SOC achieved a highly concave dose distribution that agreed well with 
the intended 50% isodose area and had a gamma pass rate of 94.9% within the target for 
4%/0.3 mm criteria. An end-to-end test of a realistic SOC application was performed with 
the mouse phantom whole liver plan, demonstrating all steps from the mouse CT scan to the 
final treatment delivery. With this plan, a conformal dose was delivered to the mouse liver 
while significantly sparing dose to the kidneys. The measured and intended target doses 
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were again in close agreement, with a gamma pass rate of 98.2%.  The ability to create and 
deliver a highly complex 2D dose distribution was also demonstrated with Audrey plan. 
 However, there is still a significant degree of error and uncertainty with the current 
SOC system. In addition to the dosimetric error discussed in Chapter 4, there are also various 
sources of geometrical uncertainty. The first is misalignment of the SOC with the primary 
collimator, which we measured to be approximately 0.7 mm at a gantry angle of 0°. 
Combined with the existing misalignment between the primary collimator and the gantry 
axis, this resulted in measured deviations from the treatment isocenter of up to 1.65 mm for 
a full gantry rotation. There is also uncertainty in the leaf calibration procedure, with leaf 
position deviations of up to 0.8 mm observed between calibrations. Leaf position 
repeatability measurements with the same calibration also showed differences of up to 0.5 
mm. Since this is well below the resolution of the encoders, it is more likely due to slight 
shifting of the motors within the SOC housing, or inconsistencies in the leaf movement 
relative to the motors. 
The largest source of geometric error is currently the subject setup. The treatment 
planning process is not yet fully automated and currently takes several hours for complex 
plans, although there is significant potential for acceleration. Therefore planning cannot yet 
be realistically performed with the subject on the couch, and the subject setup in the 
planning CT must be recreated for treatment delivery. Although this is standard practice in 
clinical treatment, the SmART system software lacks the highly automated tools used for 
reproducible patient setup in the clinic. Subject setup for SOC treatment is a much more 
manual process with greater uncertainty, likely on the order of a couple millimeters or 
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degrees of misalignment. Even with a fast, fully integrated treatment planning system, this 
error will not be completely mitigated until a more permanent (or at least more 
reproducible) SOC installation is possible, since the SOC must currently be reinstalled and 
recalibrated between imaging and treatment. It should also be noted that all measurements 
(apart from the Winston-Lutz test) were performed with EBT3 film, which has an inherent 
uncertainty of ~2%139,140 in dose and was limited by our scanning resolution of 96 dpi, which 
was used by default. This could be increased for higher resolution analysis, but at the 
expense of increased noise. 
Although these sources of geometric and dosimetric error add up to significant 
uncertainties with current SOC treatment, the majority of this error could be substantially 
reduced with integration into the SmART system. The x-ray beam is currently controlled 
with the console during SOC treatment, requiring the user to manually start and stop the 
beam. Integration with the SmART software would enable automated beam control, which 
is especially beneficial for pausing the beam if any hardware errors are detected. This would 
also allow us to develop a more accurate, automated calibration procedure using the 
projected leaf positions on the flat panel detector. More permanent installation on the SOC 
gantry, or at least a custom adapter to bypass the primary 4 x 4 cm collimator attachment, 
could significantly reduce the treatment isocenter misalignment and the potential for setup 
error between imaging and treatment. 
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5.5 Conclusions 
 The sparse orthogonal collimator was designed as a simple, more practical dose 
modulation device for small animal IMRT. This SOC design is driven by a novel direct 
aperture optimization algorithm that uses only rectangular apertures for complex dose 
modulation. With the complete SOC hardware and commissioned planning system, we 
demonstrated extremely low leaf transmission, consistent penumbra, and the ability to 
deliver conformal, complex dose distributions in close agreement with intended treatment 
plans. This novel system could considerably enhance our ability to perform clinically 
translatable animal radiation research in both cancer and non-cancer related fields. 
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